ААР — Американская академия педиатрии (American Academy of Pediatrics)
ABC — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение» (Airways-Breathing-Circulation)
АВСА3 — белковый член АТФ-связывающей кассеты АЗ
АВСВ11 — ген АТФ-связывающей кассеты, 11-й член подсемейства В (ATP-binding cassette, subfamily В member 11)
АВСВ4 — ген АТФ-связывающей кассеты, 4-й член подсемейства В (ATP-binding cassette 4 gene)
АВСС2 — ген, кодирующий 2-й член подсемейства С ABCDE — алгоритм неотложной помощи «дыхательные пути-дыхание-кровообращение-неврологический статус-внешний вид» (Airways-Breathing-Circulation-Disability-Exposure)
ABCG5/G8 — гетеродимер переносчика АТФ-связывающей кассеты ABCG5 и ABCG8 (Th eheterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
AC — до еды (при назначениях) — ante cibum
АСЕР — Американская коллегия врачей неотложной помощи (American College of Emergency Physicians)
ACOG — Американская коллегия акушеров и гинекологов (American College of Obstetricians and Gynecologists)
AHA — Американская кардиологическая ассоциация (American Heart Association)
AIS — аденокарцинома in situ (adenocarcinoma in situ)
ALTE — очевидное опасное для жизни событие (apparent life-threatening event)
APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
AUC — площадь под фармакокинетической кривой (area under the curve)
AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
ABCC2 - АТФ-связывающих кассет (ATP-binding cassette sub-family C member 2)
mTOR — мишень рапамицина в клетках млекопитающих (mammalian target ofrapamycin)
NB! — важно, обратить внимание (Nota bene)
NCI — Национальный институт рака (National Cancer Institute)
NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
NK — естественные клетки-киллеры (natural killer)
NMDA — N-метил-D-аспартат (N-methyl-D-aspartate)
NMDA — N-метил-D-аспартатные рецепторы
NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (Number Need to Treatment)
OR — отношение шансов (odds ratio)
paCO2 — парциальное давление углекислого газа в артериальной крови
PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
PANS — острый нейропсихиатрический синдром в детском возрасте (Pediatric acute-onset neuropsychiatric syndrome)
paO2 — парциальное давление кислорода в артериальной крови
PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
PC — после еды (при назначениях) — post cibum рСO2 — парциальное давление углекислого газа PCSK-9 — пропротеиновая конвертаза субтилизин-кексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
PD — плотность мощности (power density)
PD-1 — программируемая клеточная смерть 1 (англ. programmed cell death 1)
PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (Periodic Fevers with Aphthous stomatitis, Pharyngitis and Adenitis)
PIM — показатель летального исхода у детей (Pediatric Index of Mortality)
piO2 — парциальное давление кислорода
во вдыхаемом воздухе
рО2 — парциальное давление кислорода
POLG — субъединица ДНК-полимеразы у
POP — пролапс тазовых органов (pelvic organ prolapse) POP-Q — количественная оценка пролапса тазовых органов (Pelvic Organ Prolapse Quantification)
PRISA II — оценка риска госпитализации у детей II (Pediatric Risk of Admission)
PRISM — риск летального исхода у детей (Pediatric Risk of Mortality)
PRN — при (по) необходимости (Pro re nata — при возникновении обстоятельств)
PRSS — ген сериновой протеазы
PS. — примечание (Post scriptum)
PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
Q#H — каждые # часов (при назначениях) — quaque... hora
QAM — каждое утро (при назначениях) — quaque ante meridiem
QPM — каждый вечер (при назначениях) — quaque post meridiem
RAG — ген, активирующий рекомбиназу
REMS — Программа по оценке и снижению риска (Risk Evaluation and Mitigation Strategy)
RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
RF — ревматоидный фактор
Rh — резус(-фактор)
Rh«+» — резус-положительный
Rh«-» — резус-отрицательный
ROCA — Алгоритм риска развития рака яичников (Risk of Ovarian Cancer Algorithm)
ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
ROMA — Алгоритм риска наличия злокачественной опухоли яичника (Risk of Ovarian Malignancy Algorithm)
RR — относительный риск (relative risk или risk ratio)
RW — реакция Вассермана (reaction of Wassermann)
SaO2 — сатурация артериальной крови кислородом
SatO2 — насыщение крови кислородом
SCJ — зона перехода плоского эпителия в цилиндрический (Scuamocolumnar Junction)
ScvO2 — насыщение кислородом центральной венозной крови (central venous oxygen saturation)
SD — стандартное отклонение (standart deviation) SEER — эпидемиология эпиднадзора и данных о конечных результатах (Surveillance Epidemiology and End Result)
SFTPA — ген сурфактантного белка A
SFTPB — ген сурфактантного белка В
SFTPC — ген сурфактантного белка С
SILS — хирургия единого лапароскопического доступа (single-incision laparoscopic surgery)
В ходе подготовки статей по онкогинекологии для пользователей сайта МедУнивер использованы труды следующих авторов:
Alazzam M, Tidy J, Osborne R, et al: Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 1:CD008891, 2016
Alifrangis C, Agarwal R, Short D, et al: EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposidecisplatin and genetic analysis. J Clin Oncol 31(2):280, 2013
Allen JE, King MR, Farrar DF, et al: Postmolar surveillance at a trophoblastic disease center that serves indigent women. Am J Obstet Gynecol 188:1151, 2003
Azuma C, Saji F, Tokugawa Y, et al: Application of gene amplification by polymerase chain reaction to genetic analysis of molar mitochondrial DNA: the detection of anuclear empty ovum as the cause of complete mole. Gynecol Oncol 40:29, 1991
Baergen RN, Rutgers JL, Young RH, et al: Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 100:511, 2006
Benson CB, Genest DR, Bernstein MR, et al: Sonographic appearance of first trimester complete hydatidiform moles. Ultrasound Obstet Gynecol 16:188, 2000
Berkowitz RS, Bernstein MR, Harlow BL, et al: Case-control study of risk factors for partial molar pregnancy. Am J Obstet Gynecol 173:788, 1995
Berkowitz RS, Cramer DW, Bernstein MR, et al: Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol 152:1016, 1985
Berkowitz RS, Im SS, Bernstein MR, et al: Gestational trophoblastic disease: subsequent pregnancy outcome, including repeat molar pregnancy. J Reprod Med 43:81, 1998
Bolze PA, Mathe M, Hajri T, et al: First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive. Gynecol Oncol 150(2):282, 2018
Bolze PA, Riedl C, Massardier J, et al: Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ?13. Am J Obstet Gynecol 214(3):390. e1, 2016
Bower M, Newlands ES, Holden L, et al: EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 15:2636, 1997
Braga A, Campos V, Filho JR, et al: Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? Gynecol Oncol 148(2):239, 2018
Braga A, Maest? I, Matos M, et al: Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation. Gynecol Oncol 139(2):283, 2015
Braga A, Maest? I, Short D, et al: Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review. BJOG 123(8):1330, 2016
Burton JL, Lidbury EA, Gillespie AM, et al: Overdiagnosis of hydatidiform mole in early tubal ectopic pregnancy. Histopathology 38:409, 2001
Cagayan MS: Sexual dysfunction as a complication of treatment of gestational trophoblastic neoplasia. J Reprod Med 53:595, 2008
Cagayan MS, Lu-Lasala LR: Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: a 12-year review at the Phillippe General Hospital. J Reprod Med 51:785, 2006
Cao Y, Xiang Y, Feng F, et al: Surgical resection in the management of pulmonary metastatic disease of gestational trophoblastic neoplasia. Int J Gynecol Cancer 19:798, 2009
Castrillon DH, Sun D, Weremowicz S, et al: Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. Am J Surg Pathol 25:1225, 2001
Cheung AN, Khoo US, Lai CY, et al: Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole: genotyping and chromosome in situ hybridization analysis. Cancer 100:1411, 2004
Chew SH, Perlman EJ, Williams R, et al: Morphology and DNA content analysis in the evaluation of first trimester placentas for partial hydatidiform mole (PHM). Hum Pathol 31:914, 2000
Chong CY, Koh CF: Hydatidiform mole in Kandang Kerbau Hospital: a 5-year review. Singapore Med J 40:265, 1999
Cioffi R, Bergamini A, Gadducci A, et al: Reproductive outcomes after gestational trophoblastic neoplasia. A comparison between single-agent and multiagent chemotherapy: retrospective analysis from the MITO-9 group. Int J Gynecol Cancer 28(2):332, 2018
Clark RM, Nevadunsky NS, Ghosh S, et al: The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 5:194, 2010
Cole LA, Khanlian SA, Muller CY: Blood test for placental site trophoblastic tumor and nontrophoblastic malignancy for evaluating patients with low positive human chorionic gonadotropin results. J Reprod Med 53:457, 2008
Costa HL, Doyle P: Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia—a systematic review. Gynecol Oncol 100:579, 2006
Covens A, Filiaci VL, Burger RA, et al: Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Cancer 107(6):1280, 2006
Dantas PRS, Maest? I, Filho JR, et al: Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Gynecol Oncol 47(2):364, 2017
Darby S, Jolley I, Pennington S: Does chest CT matter in the staging of GTN? Gynecol Oncol 112:155, 2009
Davis MR, Howitt BE, Quade BJ, et al: Epithelioid trophoblastic tumor: a single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol 137(3):456, 2015
Dhillon T, Palmieri C, Sebire NJ, et al: Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med 51:979, 2006
Diver E, May T, Vargas R, et al: Changes in clinical presentation of postterm choriocarcinoma at the New England Trophoblastic Disease Center in recent years. Gynecol Oncol 130(3):483, 2013
Drake RD, Rao GG, McIntire DD, et al: Gestational trophoblastic disease among Hispanic women: a 21-year hospital-based study. Gynecol Oncol 103(1):81, 2006
Elias KM, Goldstein DP, Berkowitz RS: Complete hydatidiform mole in women older than age 50. J Reprod Med 55:208, 2010
Escobar PF, Lurain JR, Singh DK, et al: Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol 91:552, 2003
Essel KG, Bruegl A, Gershenson DM, et al: Salvage chemotherapy for gestational trophoblastic neoplasia: utility or futility. Gynecol Oncol 146(1):74, 2017
Eysbouts YK, Bulten J, Ottevanger PB, et al: Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol 140(1):70, 2016
Eysbouts YK, Massuger LF, IntHout J, et al: The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecol Oncol 145(3):536, 2017
Fan JB, Surti U, Taillon-Miller P, et al: Paternal origins of complete hydatidiform moles proven by whole genome single-nucleotide polymorphism haplotyping. Genomics 79:58, 2002
Ferreira EG, Maesta I, Michelin OC, et al: Assessment of quality of life and psychologic aspects in patients with gestational trophoblastic disease. J Reprod Med 54:239, 2009
FIGO Committee on Gynecologic Oncology: Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 105:3, 2009
FIGO Oncology Committee: FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet 77:285, 2002
Fleming EL, Garrett L, Growdon WB, et al: The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 53:493, 2008
Frijstein MM, Lok CA, van Trommel NE, et al: Management and prognostic factors of epithelioid trophoblastic tumors: results from the International Society for the Study of Trophoblastic Diseases database. Gynecol Oncol 152(2):361, 2019
Garner EI, Garrett A, Goldstein DP, et al: Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med 49:411, 2004
Garrett LA, Garner EI, Feltmate CM, et al: Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med 53(7):481, 2008
Ghorani E, Kaur B, Fisher RA, et al: Pembrolizumab is effective for drugresistant gestational trophoblastic neoplasia. Lancet 390(10110):2343, 2017
Gillespie AM, Lidbury EA, Tidy JA, et al: The clinical presentation, treatment, and outcome of patients diagnosed with possible ectopic molar gestation. Int J Gynecol Cancer 14:366, 2004
Gockley AA, Melamed A, Joseph NT, et al: The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. Gynecol Oncol 140(3):470, 2016
Harvey RA, Pursglove HD, Schmid P, et al: Human chorionic gonadotropin free beta-subunit measurement as a marker of placental site trophoblastic tumors. J Reprod Med 53:643, 2008
Hassadia A, Gillespie A, Tidy J, et al: Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol 99:603, 2005
Hemida R, Vos EL, El-Deek B, et al: Second uterine curettage and the number of chemotherapy courses in postmolar gestational trophoblastic neoplasia: a randomized controlled trial. Obstet Gynecol 133:1024, 2019
Homesley HD, Blessing JA, Rettenmaier M, et al: Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 72:413, 1988
Homesley HD, Blessing JA, Schlaerth J, et al: Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecol Oncol 39:305, 1990
Hui P, Baergen R, Cheung AN, et al: Gestational trophoblastic neoplasia. In Kurman RJ, Carcangiu LM, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs. Lyon, International Agency for Research on Cancer, 2014a, p 155
Hui P, Baergen R, Cheung AN, et al: Molar pregnancies. In Kurman RJ, Carcangiu LM, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs. Lyon, International Agency for Research on Cancer, 2014b, p 163
Hyman DM, Bakios L, Gualtiere G, et al: Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecol Oncol 129(1):58, 2013
Jauniaux E: Partial moles: from postnatal to prenatal diagnosis. Placenta 20: 379, 1999
Johns J, Greenwold N, Buckley S, et al: A prospective study of ultrasound screening for molar pregnancies in missed miscarriages. Ultrasound Obstet Gynecol 25:493, 2005
Joneborg U, Eloranta S, Johansson AL, et al: Hydatidiform mole and subsequent pregnancy outcome: a population-based cohort study. Am J Obstet Gynecol 211(6):681.e1, 2014
Kang WD, Choi HS, Kim SM: Weekly methotrexate (50mg/m2) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. Gynecol Oncol 117(3):477, 2010
Khan F, Everard J, Ahmed S, et al: Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects. Br J Cancer 89:2197, 2003
Khanlian SA, Smith HO, Cole LA: Persistent low levels of human chorionic gonadotropin: a premalignant gestational trophoblastic disease. Am J Obstet Gynecol 188:1254, 2003
Kim SJ, Lee C, Kwon SY, et al: Studying changes in the incidence, diagnosis and management of GTD: the South Korean model. J Reprod Med 49:643, 2004
Kohorn EI: Persistent low-level «real» human chorionic gonadotropin: a clinical challenge and a therapeutic dilemma. Gynecol Oncol 85:315, 2002
La Vecchia C, Parazzini F, Decarli A, et al: Age of parents and risk of gestational trophoblastic disease. J Natl Cancer Inst 73:639, 1984
Lavie I, Rao GG, Castrillon DH, et al: Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles. Am J Obstet Gynecol 192:1362, 2005
Lawler SD, Fisher RA: Genetic studies in hydatidiform mole with clinical correlations. Placenta 8:77, 1987
Lawler SD, Fisher RA, Dent J: A prospective genetic study of complete and partial hydatidiform moles. Am J Obstet Gynecol 164:1270, 1991
Lawrie TA, Alazzam M, Tidy J, et al: First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 6:CD007102, 2016
Lazarus E, Hulka C, Siewert B, et al: Sonographic appearance of early complete molar pregnancies. J Ultrasound Med 18:589, 1999
Lee KH, Lee IH, Kim BG, et al: Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study. Int J Gynecol Cancer 19:84, 2009
Li L, Wan X, Feng F, et al: Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia. BMC Cancer 18(1):585, 2018
Limpongsanurak S: Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 46:110, 2001
Lin LH, Maest? I, Braga A, et al: Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: a retrospective multicenter cohort and literature review. Gynecol Oncol 145(1):88, 2017
Lindholm H, Flam F: The diagnosis of molar pregnancy by sonography and gross morphology. Acta Obstet Gynecol Scand 78:6, 1999
Lok CA, Ansink AC, Grootfaam D, et al: Treatment and prognosis of post term choriocarcinoma in The Netherlands. Gynecol Oncol 103:698, 2006
Lok CA, van der Houwen C, ten Kate-Booji MJ, et al: Pregnancy after EMA/ CO for gestational trophoblastic disease: a report from The Netherlands. BJOG 110:560, 2003
Loukovaara M, Pukkala E, Lehtovirta P, et al: Epidemiology of hydatidiform mole in Finland, 1975 to 2001. Eur J Gynaecol Oncol 26:207, 2005
Lu WG, Ye F, Shen YM, et al: EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Int J Gynecol Cancer 18:357, 2008
Lybol C, Sweep FC, Harvey R, et al: Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 125(3):576, 2012
Lybol C, Thomas CM, Bulten J, et al: Increase in the incidence of gestational trophoblastic disease in The Netherlands. Gynecol Oncol 121(2):334, 2011
Mackenzie F, Mathers A, Kennedy J: Invasive hydatidiform mole presenting as an acute primary haemoperitoneum. BJOG 100:953, 1993
Maeste I, Nitecki R, Horowitz NS, et al: Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol 148(1):161, 2018
Mangili G, Cioffi R, Danese S, et al: Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. Gynecol Oncol 151(3):449, 2018
Marcorelles P, Audrezet MP, Le Bris MJ, et al: Diagnosis and outcome of complete hydatidiform mole coexisting with a live twin fetus. Eur J Obstet Gynecol Reprod Biol 118:21, 2005
Massad LS, Abu-Rustum NR, Lee SS, et al: Poor compliance with postmolar surveillance and treatment protocols by indigent women. Obstet Gynecol 96:940, 2000
Matsui H, Iitsuka Y, Yamazawa K, et al: Changes in the incidence of molar pregnancies: a population-based study in Chiba Prefecture and Japan between 1974 and 2000. Hum Reprod 18:172, 2003
Matsui H, Sekiya S, Hando T, et al: Hydatidiform mole coexistent with a twin live fetus: a national collaborative study in Japan. Hum Reprod 15:608, 2000
McNeish IA, Strickland S, Holden L, et al: Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 20:1838, 2002
Merchant SH, Amin MB, Viswanatha DS, et al: p57KIP2 immunohistochemistry in early molar pregnancies: emphasis on its complementary role in the differential diagnosis of hydropic abortuses. Hum Pathol 36:180, 2005
Mungan T, Kuscu E, Dabakoglu T, et al: Hydatidiform mole: clinical analysis of 310 patients. Int J Gynaecol Obstet 52:233, 1996
National Comprehensive Cancer Network: Gestational trophoblastic neoplasia, version 1.2019. Plymouth Meeting, National Comprehensive Cancer Network, 2018
Newlands ES, Holden L, Seckl MJ, et al: Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 47:465, 2002
Newlands ES, Mulholland PJ, Holden L, et al: Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 18:854, 2000
Ngan HY: The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J Gynecol Cancer 14:202, 2004
Numnum TM, Leath CA III, Straughn JM Jr, et al: Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy. Gynecol Oncol 97:713, 2005
Olsen TG, Hubert PR, Nycum LR: Falsely elevated human chorionic gonadotropin leading to unnecessary therapy. Obstet Gynecol 98:843, 2001
Osborne R, Filiaci V, Schink J, et al: A randomized phase III trial comparing weekly parenteral methotrexate and «pulsed» dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. Gynecol Oncol 108:S2, 2008
Osborne RJ, Filiaci VL, Schink JC, et al: Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol 128(3):5352016, 2016
Padran L, Rezende Filho J, Amim Junior J, et al: Manual compared with electric vacuum aspiration for treatment of molar pregnancy. Obstet Gynecol 131(4):652, 2018
Palmer JE, Macdonald M, Wells M, et al: Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med 53:465, 2008
Palmer JR, Driscoll SG, Rosenberg L, et al: Oral contraceptive use and risk of gestational trophoblastic tumors. J Natl Cancer Inst 91:635, 1999
Palmieri C, Dhillon T, Fisher RA, et al: Management and outcome of healthy women with a persistently elevated beta-hCG. Gynecol Oncol 106:35, 2007
Papadopoulos AJ, Foskett M, Seckl MJ, et al: Twenty-five years’ clinical experience with placental site trophoblastic tumors. J Reprod Med 47:460, 2002
Paradinas FJ, Fisher RA, Browne P, et al: Diploid hydatidiform moles with fetal red blood cells in molar villi: 1. Pathology, incidence, and prognosis. J Pathol 181:183, 1997
Parazzini F, Cipriani S, Mangili G, et al: Oral contraceptives and risk of gestational trophoblastic disease. Contraception 65:425, 2002
Parazzini F, La Vecchia C, Mangili G, et al: Dietary factors and risk of trophoblastic disease. Am J Obstet Gynecol 158:93, 1988 Parazzini F, La Vecchia C, Pampallona S: Parental age and risk of complete and partial hydatidiform mole. BJOG 93:582, 1986
Parazzini F, Mangili G, La Vecchia C, et al: Risk factors for gestational trophoblastic disease: a separate analysis of complete and partial hydatidiform moles. Obstet Gynecol 78:1039, 1991
Patel SM, Desai A: Management of drug resistant gestational trophoblastic neoplasia. J Reprod Med 55:296, 2010
Pisal N, North C, Tidy J, et al: Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol 87:190, 2002
Powles T, Savage P, Short D, et al: Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate? Br J Cancer 94:51, 2006
Price JM, Hancock BW, Tidy J, et al: Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia. J Reprod Med 55:301, 2010
Rodabaugh KJ, Bernstein MR, Goldstein DP, et al: Natural history of postterm choriocarcinoma. J Reprod Med 43:75, 1998
Ronnett BM, DeScipio C, Murphy KM: Hydatidiform moles: ancillary techniques to refine diagnosis. Int J Gynecol Pathol 30(2):101, 2011
Rotmensch S, Cole LA: False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 355:712, 2000
Rustin GJ, Newlands ES, Lutz JM, et al: Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 14:2769, 1996
Savage P, Cooke R, O’Nions J, et al: Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol 33(5):472, 2015a
Savage P, Kelpanides I, Tuthill M, et al: Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol 137(1):73, 2015b
Schechter NR, Mychalczak B, Jones W, et al: Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. Gynecol Oncol 68:183, 1998
Schmid P, Nagai Y, Agarwal R, et al: Prognostic markers and long-term outcome of placental-site trophoblastic tumors: a retrospective observational study. Lancet 374:48, 2009
Sebire NJ, Fisher RA, Foskett M, et al: Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG 110:22, 2003
Sebire NJ, Foskett M, Fisher RA, et al: Persistent gestational trophoblastic disease is rarely, if ever, derived from nonmolar first-trimester miscarriage. Med Hypoth 64:689, 2005a
Sebire NJ, Foskett M, Short D, et al: Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. BJOG 114:760, 2007
Sebire NJ, Lindsay I, Fisher RA, et al: Overdiagnosis of complete and partial hydatidiform mole in tubal ectopic pregnancies. Int J Gynecol Pathol 24:260, 2005b
Sebire NJ, Rees H, Paradinas F, et al: The diagnostic implications of routine ultrasound examination in histologically confirmed early molar pregnancies. Ultrasound Obstet Gynecol 18:662, 2001
Seckl MJ, Fisher RA, Salerno G, et al: Choriocarcinoma and partial hydatidiform moles. Lancet 356:36, 2000
Seckl MJ, Rustin GJS, Newlands ES, et al: Pulmonary embolism, pulmonary hypertension, and choriocarcinoma. Lancet 338:1313, 1991
Sharma S, Jagdev S, Coleman RE, et al: Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer 81:1037, 1999
Shih IM, Kurman RJ: Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 22:1393, 1998
Sita-Lumsden A, Short D, Lindsay I, et al: Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. Br J Cancer 107(11): 1810, 2012
Smith HO, Hilgers RD, Bedrick EJ, et al: Ethnic differences at risk for gestational trophoblastic disease in New Mexico: a 25-year population-based study. Am J Obstet Gynecol 188:357, 2003
Soto-Wright V, Bernstein M, Goldstein DP, et al: The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 86:775, 1995
Sun SY, Melamed A, Goldstein DP, et al: Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol 138(1):46, 2015
Sun SY, Melamed A, Joseph NT, et al: Clinical presentation of complete hydatidiform mole and partial hydatidiform mole at a regional trophoblastic disease center in the United States over the past 2 decades. Int J Gynecol Cancer 26(2):367, 2016
Taylor F, Grew T, Everard J, et al: The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. Eur J Cancer 49(15):3184, 2013a
Taylor JS, Viera L, Caputo TA, et al: Unsuccessful planned conservative resection of placental site trophoblastic tumor. Obstet Gynecol 121(2 Pt 2 Suppl 1): 465, 2013b
Tham BW, Everard JE, Tidy JA, et al: Gestational trophoblastic disease in the Asian population of northern England and North Wales. BJOG 110:555, 2003
Tidy JA, Rustin GJ, Newlands ES, et al: Presentation and management of choriocarcinoma after nonmolar pregnancy. BJOG 102:715, 1995 Tuncer ZS, Bernstein MR, Goldstein DP, et al: Outcome of pregnancies occurring within 1 year of hydatidiform mole. Obstet Gynecol 94:588, 1999
Uberti EM, Fajardo MD, da Cunha AG, et al: Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general followup or subsequent treatment. Gynecol Oncol 114:299, 2009
van Trommel NE, Lok CA, Bulten H, et al: Long-term outcome of placental site trophoblastic tumor in The Netherlands. J Reprod Med 58(5-6):224, 2013
van Trommel NE, Massuger LF, Verheijen RH, et al: The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol 99:6, 2005
Vargas R, Barroilhet LM, Esselen K, et al: Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 59(5-6):188, 2014
Wang J, Short D, Sebire NJ, et al: Salvage chemotherapy of relapsed or highrisk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol 19:1578, 2008
Wang Q, Fu J, Hu L, et al: Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 9:CD007289, 2017
Wenzel L, Berkowitz R, Robinson S, et al: The psychological, social, and sexual consequences of gestational trophoblastic disease. Gynecol Oncol 46:74, 1992
Williams J, Short D, Dayal L, et al: Effect of early pregnancy following chemotherapy on diseaserelapse and fetal outcome in women treated for gestational trophoblastic neoplasia. J Reprod Med 59(5-6):248, 2014
Wolfberg AJ, Feltmate C, Goldstein DP, et al: Low risk of relapse after achieving undetectable hCG levels in women with complete molar pregnancy. Obstet Gynecol 104:551, 2004
Wong JM, Liu D, Lurain JR: Reproductive outcomes after multiagent chemotherapy forhigh-risk gestational trophoblastic neoplasia. J Reprod Med 59(5-6):204, 2014
Yarandi F, Eftekhar Z, Shojaei H, et al: Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet 103:33, 2008
Zhao J, Lv WG, Feng FZ, et al: Placental site trophoblastic tumor: a review of 108 cases and their implications for prognosis and treatment. Gynecol Oncol 142(1):102, 2016
Zhou Q, Lei XY, Xie Q, et al: Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience. J Ultrasound Med 24:15, 2005
Aboud E: A review of granulosa cell tumours and thecomas of the ovary. Arch Gynecol Obstet 259:161, 1997
Abu-Rustum NR, Restivo A, Ivy J, et al: Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol 103:31, 2006
Ameryckx L, Fatemi HM, De Sutter P, et al: GnRH antagonist in the adjuvant treatment of a recurrent ovarian granulosa cell tumor: a case report. Gynecol Oncol 99:764, 2005
Aoki Y, Kase H, Fujita K, et al: Dysgerminoma with a slightly elevated alphafetoprotein level diagnosed as a mixed germ cell tumor after recurrence. Gynecol Obstet Invest 55:58, 2003
Beiner ME, Gotlieb WH, Korach Y, et al: Cystectomy for immature teratoma of the ovary. Gynecol Oncol 93:381, 2004
Bentivegna E, Aza?s H, Uzan C, et al: Surgical outcomes after debulking surgery for intraabdominal ovarian growing teratoma syndrome: analysis of 38 cases. Ann Surg Oncol 22(3 suppl):S964, 2015
Billmire D, Vinocur C, Rescorla F, et al: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 39:424, 2004
Billmire DF, Cullen JW, Rescorla FJ, et al: Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children’s Oncology Group. J Clin Oncol 32(5):465, 2014
Bonazzi C, Peccatori F, Colombo N, et al: Pure ovarian immature teratoma, a unique and curable disease: 10 years’ experience of 32 prospectively treated patients. Obstet Gynecol 84:598, 1994
Boyce EA, Costaggini I, Vitonis A, et al: The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol 115:221, 2009
Brown J, Brady WE, Schink J, et al: Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 120(3):344, 2014a
Brown J, Friedlander M, Backes FJ, et al: Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer 24(9 Suppl 3):S48, 2014b
Brown J, Shvartsman HS, Deavers MT, et al: The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord–stromal ovarian tumors. Gynecol Oncol 97:489, 2005
Brown J, Shvartsman HS, Deavers MT, et al: The activity of taxanes in the treatment of sex cord–stromal ovarian tumors. J Clin Oncol 22:3517, 2004
Brown J, Sood AK, Deavers MT, et al: Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 113:86, 2009
Burton ER, Brady M, Homesley HD, et al: A phase II study of paclitaxel for the treatment of ovarian stromal tumors: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 140(1):48, 2016
Carmina E, Rosato F, Janni A, et al: Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 91:2, 2006
Cass DL, Hawkins E, Brandt ML, et al: Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg 36:693, 2001
Cathro HP, Stoler MH: The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 36:195, 2005
Chan JK, Cheung MK, Husain A, et al: Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108:521, 2006
Chan JK, Tewari KS, Waller S, et al: The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol 98:111, 2008
Chan JK, Zhang M, Kaleb V, et al: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary: a multivariate analysis. Gynecol Oncol 96:204, 2005
Chechia A, Attia L, Temime RB, et al: Incidence, clinical analysis, and management of ovarian fibromas and fibrothecomas. Am J Obstet Gynecol 199:473e1, 2008
Chen CA, Lin H, Weng CS, et al: Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study. Eur J Cancer 50(18):3161, 2014
Chen VW, Ruiz B, Killeen JL, et al: Pathology and classification of ovarian tumors. Cancer 97:2631, 2003
Cheng H, Peng J, Yang Z, et al: Prognostic significance of lymphadenectomy in malignant ovarian sex cord stromal tumor: a retrospective cohort study and meta-analysis. Gynecol Oncol 148(1):91, 2018
Cicin I, Saip P, Guney N, et al: Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Eur J Obstet Gynecol Reprod Biol 146:210, 2009
Colombo N, Parma G, Zanagnolo V, et al: Management of ovarian stromal cell tumors. J Clin Oncol 25:2944, 2007
Corakci A, Ozeren S, Ozkan S, et al: Pure nongestational choriocarcinoma of ovary. Arch Gynecol Obstet 271:176, 2005
Crew KD, Cohen MH, Smith DH, et al: Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol 96:235, 2005
Culine S, Lhomme C, Michel G, et al: Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy. J Surg Oncol 62:40, 1996
Curtin JP, Morrow CP, D’Ablaing G, et al: Malignant germ cell tumors of the ovary: 20-year report of LAC-USC Women’s Hospital. Int J Gynecol Cancer 4:29, 1994
Cushing B, Giller R, Ablin A, et al: Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the Pediatric Oncology Group and the Children’s Cancer Group. Am J Obstet Gynecol 181:353, 1999
Dark GG, Bower M, Newlands ES, et al: Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15:620, 1997
Dimopoulos MA, Papadimitriou C, Hamilos G, et al: Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol 95:695, 2004
Dos Santos L, Mok E, Iasonos A, et al: Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol 105:321, 2007
Dubuc-Lissoir J, Berthiaume MJ, Boubez G, et al: Bone metastasis from a granulosa cell tumor of the ovary. Gynecol Oncol 83:400, 2001
East N, Alobaid A, Goffin F, et al: Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 27:363, 2005
Elit L, Bocking A, Kenyon C, et al: An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Gynecol Oncol 72:123, 1999
Fishman A, Kudelka AP, Tresukosol D, et al: Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med 41:393, 1996
Frausto SD, Geisler JP, Fletcher MS, et al: Late recurrence of juvenile granulosa cell tumor of the ovary. Am J Obstet Gynecol 1:366, 2004
Gainford MC, Tinker A, Carter J, et al: Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. An Australia New Zealand Gynaecological Oncology Group (ANZGOG) and Gynaecologic Cancer Intergroup (GCIG) study. Int J Gynecol Cancer 20:75, 2010
Galani E, Alamanis C, Dimopoulos MA: Familial female and male germ cell cancer: a new syndrome? Gynecol Oncol 96:254, 2005
Gershenson DM, Morris M, Burke TW, et al: Treatment of poor-prognosis sex cord–stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 87:527, 1996
Gershenson DM, Morris M, Cangir A, et al: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 8:715, 1990
Hardy RD, Bell JG, Nicely CJ, et al: Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 96:865, 2005
Hasiakos D, Papakonstantinou K, Goula K, et al: Juvenile granulosa cell tumor associated with pregnancy: report of a case and review of the literature. Gynecol Oncol 100(2):426, 2006
Heravi-Moussavi A, Anglesio MS, Cheng SW, et al: Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 366(3):234, 2012
Hoepffner W, Horn LC, Simon E, et al: Gonadoblastomas in 5 patients with 46,XY gonadal dysgenesis. Exp Clin Endocrinol Diabetes 113:231, 2005
Homesley HD, Bundy BN, Hurteau JA, et al: Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 72:131, 1999
Horbelt D, Delmore J, Meisel R, et al: Mixed germ cell malignancy of the ovary concurrent with pregnancy. Obstet Gynecol 84:662, 1994
Hsu YJ, Pai L, Chen YC, et al: Extragonadal germ cell tumors in Taiwan: an analysis of treatment results of 59 patients. Cancer 95:766, 2002
Jung SE, Rha SE, Lee JM, et al: CT and MRI findings of sex cord–stromal tumor of the ovary. AJR Am J Roentgenol 185:207, 2005
Kalfa N, Patte C, Orbach D, et al: A nationwide study of granulosa cell tumors in pre- and postpubertal girls: missed diagnosis of endocrine manifestations worsens prognosis. J Pediatr Endocrinol Metab 18:25, 2005
Kim SH, Kang SB: Ovarian dysgerminoma: color Doppler ultrasonographic findings and comparison with CT and MR imaging findings. J Ultrasound Med 14:843, 1995
Kleppe M, Amkreutz LC, Van Gorp T, et al: Lymph-node metastasis in stage I and II sex cord stromal and malignant germ cell tumours of the ovary: a systematic review. Gynecol Oncol 133(1):124, 2014
Kobel M, Gilks CB, Huntsman DG: Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res 69:9160, 2009
Kumar S, Shah JP, Bryant CS, et al: The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol 110:125, 2008
Kurihara S, Hirakawa T, Amada S, et al: Inhibin-producing ovarian granulosa cell tumor as a cause of secondary amenorrhea: case report and review of the literature. J Obstet Gynaecol Res 30:439, 2004
Kurman RJ, Carcangiu ML, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon, International Agency for Research on Cancer, 2014
Kusamura S, Teixeira LC, dos Santos MA, et al: Ovarian germ cell cancer: clinicopathologic analysis and outcome of 31 cases. Tumori 86:450, 2000
LaPolla JP, Fiorica JV, Turnquist D, et al: Successful therapy of metastatic embryonal carcinoma coexisting with gonadoblastoma in a patient with 46,XY pure gonadal dysgenesis (Swyer’s syndrome). Gynecol Oncol 37:417, 1990
Leblanc E, Querleu D, Narducci F, et al: Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience. Gynecol Oncol 94:624, 2004
Lee YK, Park NH, Kim JW, et al: Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 18:642, 2008
Li H, Hong W, Zhang R, et al: Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma. Chin Med J (Engl) 115:1496, 2002
Li J, Yang W, Wu X: Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol 105:769, 2007
Liu Q, Ding X, Yang J, et al: The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol 131(3):551, 2013
Low JJ, Perrin LC, Crandon AJ, et al: Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors: a review of 74 cases. Cancer 89:391, 2000
Majzlin G, Stevens FL: Meigs’ syndrome. Case report and review of literature. J Int Coll Surg 42:625, 1964
Marelli G, Carinelli S, Mariani A, et al: Sclerosing stromal tumor of the ovary: report of eight cases and review of the literature. Eur J Obstet Gynecol Reprod Biol 76:85, 1998
Marina NM, Cushing B, Giller R, et al: Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a Pediatric Oncology Group/Children’s Cancer Group Intergroup study. J Clin Oncol 17:2137, 1999
Martin-Jimenez A, Condom-Munro E, Valls-Porcel M, et al: [Gynandroblastoma of the ovary: review of the literature.] French. J Gynecol Obstet Biol Reprod (Paris) 23:391, 1994
McKenna M, Kenny B, Dorman G, et al: Combined adult granulosa cell tumor and mucinous cystadenoma of the ovary: granulosa cell tumor with heterologous mucinous elements. Int J Gynecol Pathol 24:224, 2005
Messing MJ, Gershenson DM, Morris M, et al: Primary treatment failure in patients with malignant ovarian germ cell neoplasms. Int J Gynecol Cancer 2:295, 1992
Miller BE, Barron BA, Dockter ME, et al: Parameters of differentiation and proliferation in adult granulosa cell tumors of the ovary. Cancer Detect Prev 25:48, 2001
Mom CH, Engelen MJ, Willemse PH, et al: Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 105:365, 2007
Morgan RJ Jr, Armstrong DK, Alvarez RD, et al: Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14(9):1134, 2016
Morimura Y, Nishiyama H, Yanagida K, et al: Dysgerminoma with syncytiotrophoblastic giant cells arising from 46,XX pure gonadal dysgenesis. Obstet Gynecol 92:654, 1998
Murugaesu N, Schmid P, Dancey G, et al: Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 24:4862, 2006
Nasioudis D, Chapman-Davis E, Frey MK, et al: Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecol Oncol 147(2):296, 2017
O’Connor DM, Norris HJ: The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 13:283, 1994
Okada I, Nakagawa S, Takemura Y, et al: Ovarian thecoma associated in the first trimester of pregnancy. J Obstet Gynaecol Res 30:368, 2004
Oliva E, Alvarez T, Young RH: Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol 29:143, 2005
Oliva E, Andrada E, Pezzica E, et al: Ovarian carcinomas with choriocarcinomatous differentiation. Cancer 72:2441, 1993
Outwater EK, Marchetto B, Wagner BJ: Virilizing tumors of the ovary: imaging features. Ultrasound Obstet Gynecol 15:365, 2000
Paladini D, Testa A, Van Holsbeke C, et al: Imaging in gynecological disease (5): clinical and ultrasound characteristics in fibroma and fibrothecoma of the ovary. Ultrasound Obstet Gynecol 34:188, 2009
Palenzuela G, Martin E, Meunier A, et al: Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg 248:836, 2008
Park JY, Kim DY, Suh DS, et al: Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol 145(3):513, 2017
Pavlakis K, Messini I, Vrekoussis T, et al: Intraoperative assessment of epithelial and non-epithelial ovarian tumors: a 7-year review. Eur J Gynaecol Oncol 30:657, 2009
Pena-Alonso R, Nieto K, Alvarez R, et al: Distribution of Y-chromosomebearing cells in gonadoblastoma and dysgenetic testis in 45,X/46,XY infants. Mod Pathol 18:439, 2005
Pins MR, Young RH, Daly WJ, et al: Primary squamous cell carcinoma of the ovary: report of 37 cases. Am J Surg Pathol 20:823, 1996
Powell JL, Connor GP, Henderson GS: Management of recurrent juvenile granulosa cell tumor of the ovary. Gynecol Oncol 81:113, 2001
Pressley RH, Muntz HG, Falkenberry S, et al: Serum lactic dehydrogenase as a tumor marker in dysgerminoma. Gynecol Oncol 44:281, 1992
Quirk JT, Natarajan N: Ovarian cancer incidence in the United States, 1992– 1999. Gynecol Oncol 97:519, 2005
Ray-Coquard I, Brown J, Harter P, Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer 24(9 Suppl 3):S42, 2014
Rezk Y, Sheinfeld J, Chi DS: Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature. Gynecol Oncol 96:883, 2005
Schneider DT, Calaminus G, Harms D, et al: Ovarian sex cord–stromal tumors in children and adolescents. J Reprod Med 50:439, 2005
Schneider DT, Calaminus G, Wessalowski R, et al: Ovarian sex cord–stromal tumors in children and adolescents. J Clin Oncol 21:2357, 2003
Schrader KA, Gorbatcheva B, Senz J, et al: The specificity of the FLXL2 c.402G>G somatic mutation: a survey of solid tumors. PLoS One 4(11):e7988, 2009
Schwartz PE, Morris JM: Serum lactic dehydrogenase: a tumor marker for dysgerminoma. Obstet Gynecol 72:511, 1988
Seagle BL, Ann P, Butler S, et al: Ovarian granulosa cell tumor: a National Cancer Database study. Gynecol Oncol 146(2):285, 2017
Shah R, Xia C, Krailo M, et al: Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecol Oncol 150(2):253, 2018
Shah SP, Kobel M, Senz J, et al: Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360:2719, 2009
Sharony R, Aviram R, Fishman A, et al: Granulosa cell tumors of the ovary: do they have any unique ultrasonographic and color Doppler flow features? Int J Gynecol Cancer 11:229, 2001
Shim SH, Kim DY, Lee SW, et al: Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes. Int J Gynecol Cancer 23(2):249, 2013
Shimizu Y, Komiyama S, Kobayashi T, et al: Successful management of endodermal sinus tumor of the ovary associated with pregnancy. Gynecol Oncol 88:447, 2003
Siddiqui M, Toub DB: Cellular fibroma of the ovary with Meigs’ syndrome and elevated CA-125: a case report. J Reprod Med 40:817, 1995
Skalleberg J, Solheim O, Foss? SD, et al: Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. Gynecol Oncol 145(1):148, 2017
Smith HO, Berwick M, Verschraegen CF, et al: Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 107:1075, 2006
Solheim O, Gershenson DM, Trop? CG, Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978–2010). Eur J Cancer 50(11):1942, 2014
Solheim O, Kaern J, Trop? CG, et al: Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). Gynecol Oncol 131(2):330, 2013
Solheim O, Trop? CG, Rokkones E, et al: Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the “cisplatin era.” Gynecol Oncol 136(2):224, 2015
Stettner AR, Hartenbach EM, Schink JC, et al: Familial ovarian germ cell cancer: report and review. Am J Med Genet 84:43, 1999
Stevens TA, Brown J, Zander DS, et al: Adult granulosa cell tumors of the ovary in two first-degree relatives. Gynecol Oncol 98:502, 2005
Stier EA, Barakat RR, Curtin JP, et al: Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol 87:737, 1996 Takemori M, Nishimura R, Yamasaki M, et al: Ovarian mixed germ cell tumor composed of polyembryoma and immature teratoma. Gynecol Oncol 69:260, 1998
Talukdar S, Kumar S, Bhatla N, et al: Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol 132(1):28, 2014
Tangir J, Zelterman D, Ma W, et al: Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 101:251, 2003
Teilum G: Classification of endodermal sinus tumour (mesoblastoma vitellinum) and so-called “embryonal carcinoma” of the ovary. Acta Pathol Microbiol Scand 64:407, 1965
Ulbright TM: Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 18 (Suppl 2):S61, 2005
Uygun K, Aydiner A, Saip P, et al: Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary. Gynecol Oncol 88:400, 2003
van Meurs HS, Bleeker MC, van der Velden J, et al: The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. Int J Gynecol Cancer 23(8):1417, 2013
van Meurs HS, Buist MR, Westermann AM, et al: Effectiveness of chemotherapy in measurable granulosa cell tumors: a retrospective study and review of literature. Int J Gynecol Cancer 24(3):496, 2014
Vang R, Herrmann ME, Tavassoli FA: Comparative immunohistochemical analysis of granulosa and Sertoli components in ovarian sex cord–stromal tumors with mixed differentiation: potential implications for derivation of Sertoli differentiation in ovarian tumors. Int J Gynecol Pathol 23:151, 2004
Vicus D, Beiner ME, Klachook S, et al: Pure dysgerminoma of the ovary 35 years on: a single institutional experience. Gynecol Oncol 117:23, 2010
Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435, 1987
Williams SD, Blessing JA, DiSaia PJ, et al: Second-look laparotomy in ovarian germ cell tumors: the Gynecologic Oncology Group experience. Gynecol Oncol 52:287, 1994
Williams SD, Kauderer J, Burnett AF, et al: Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol 95:496, 2004
Wolf JK, Mullen J, Eifel PJ, et al: Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol 73:35, 1999
Young JL Jr, Wu XC, Roffers SD, et al: Ovarian cancer in children and young adults in the United States, 1992–1997. Cancer 97:2694, 2003
Young RH: Sex cord–stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 18:S81, 2005
Young RH, Dudley AG, Scully RE: Granulosa cell, Sertoli–Leydig cell, and unclassified sex cord–stromal tumors associated with pregnancy: a clinicopathological analysis of thirty-six cases. Gynecol Oncol 18:181, 1984
Young RH, Scully RE: Ovarian Sertoli–Leydig cell tumors: a clinicopathological analysis of 207 cases. Am J Surg Pathol 9:543, 1985
Young RH, Welch WR, Dickersin GR, et al: Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer 50:1384, 1982
Yuan JQ, Lin XN, Xu JY, et al: Ovarian juvenile granulosa cell tumor associated with Maffucci’s syndrome: case report. Chin Med J 117:1592, 2004
Zaloudek C, Norris HJ: Sertoli-Leydig tumors of the ovary: a clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol 8:405, 1984
Zanagnolo V, Pasinetti B, Sartori E: Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 25:431, 2004
Zanetta G, Bonazzi C, Cantu M, et al: Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 19:1015, 2001
Zhang M, Cheung MK, Shin JY, et al: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—an analysis of 376 women. Gynecol Oncol 104:396, 2007
Zhao XY, Huang HF, Lian LJ, et al: Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 16:8, 2006
Al-Barrak J, Santos JL, Tinker A, et al: Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. Gynecol Oncol 122(1):107, 2011
Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950, 1996
Aletti GD, Dowdy SC, Gostout BS, et al: Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg 208:614, 2009
Aletti GD, Dowdy SC, Podratz KC, et al: Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100:283, 2006
Alsop K, Fereday S, Meldrum C, et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654, 2012
Alvarado-Cabrero I, Cheung A, Caduff R: Tumours of the fallopian tube and uterine ligaments [Tumours of the fallopian tube]. In Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours. Geneva, WHO, 2003, p 206
American College of Obstetricians and Gynecologists: Evaluation and management of adnexal masses. Practice Bulletin No. 174, November 2016
American College of Obstetricians and Gynecologists: Hereditary breast and ovarian cancer syndrome. Practice Bulletin No. 182, September 2017a
American College of Obstetricians and Gynecologists: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Committee Opinion No. 716, September 2017b
American College of Obstetricians and Gynecologists: Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. Committee Opinion No. 774, March 2019
Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34, 2006
Beiner ME, Finch A, Rosen B, et al: The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations: a prospective study. Gynecol Oncol 104(1):7, 2007
Bell J, Brady MF, Young RC, et al: Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102:432, 2006
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, et al: Gynecologic Cancer Intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer 24(9 suppl 3):S55, 2014
Bloomfield HE, Olson A, Greer N, et al: Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med 161(1):46, 2014
Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419, 2009
Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394, 2018
Bristow RE, Palis BE, Chi DS, et al: The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 118:262, 2010
Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473, 2011
Burstein HJ, Mangu PB, Somerfield MR, et al: American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29(24):3328, 2011
Buttin BM, Herzog TJ, Powell MA, et al: Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 99:11, 2002
Carlson JW, Miron A, Jarboe EA, et al: Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 26:4160, 2008
Chan JK, Brady MF, Penson RT, et al: Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374(8):738, 2016
Chan JK, Munro EG, Cheung MK, et al: Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109:12, 2007
Chan JK, Tian C, Fleming GF, et al: The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 116:301, 2010a
Chan JK, Tian C, Teoh D, et al: Survival after recurrence in early-stage highrisk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 116:307, 2010b
Chi DS, Abu-Rustum NR, Sonoda Y, et al: The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 192:1614, 2005
Chi DS, Eisenhauer EL, Zivanovic O, et al: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26, 2009a
Chi DS, McCaughty K, Diaz JP, et al: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933, 2006
Chi DS, Phaeton R, Miner TJ, et al: A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist 14:835, 2009b
Chi DS, Ramirez PT, Teitcher JB, et al: Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol 25(31):4946, 2007
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303, 2008
Cramer DW, Vitonis AF, Terry KL, et al: The association between talc use and ovarian cancer: a retrospective case-control study in two US states. Epidemiology 27(3):334, 2016
Crane EK, Sun CC, Ramirez PT, et al: The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol 136(1):25, 2015
Cress RD, Bauer K, O’Malley CD, et al: Surgical staging of early stage epithelial ovarian cancer: results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol 121:94, 2011
Delle Marchette M, Ceppi L, Andreano A, et al: Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery. Eur J Cancer 111:61, 2019
Doyle C, Crump M, Pintilie M, et al: Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266, 2001
du Bois A, Ewald-Riegler N, de Gregorio N, et al: Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gyn?kologische Onkologie (AGO) Study Group. Eur J Cancer 49(8):1905, 2013
du Bois A, Floquet A, Kim JW, et al: Incorporation of pazopanib in maintenance therapy of ovarian cancer J Clin Oncol 32(30):3374, 2014
du Bois A, Luck HJ, Meier W, et al: A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320, 2003
Earle CC, Schrag D, Neville BA, et al: Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98:172, 2006
Eichhorn JH, Young RH, Scully RE: Primary ovarian small cell carcinoma of pulmonary type: a clinicopathologic, immunohistologic, and flow cytometric analysis of 11 cases. Am J Surg Pathol 16:926, 1992
Elder JW, Pavlik EJ, Long A, et al: Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. Gynecol Oncol 135(1):8, 2014
Engelen MJ, Kos HE, Willemse PH, et al: Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106:589, 2006
Fagotti A, Fanfani F, Ludovisi M, et al: Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 96(3):729, 2005
Fagotti A, Vizzielli G, De Iaco P, et al: A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 209(5):462.e1, 2013
Falconer H, Yin L, Gr?nberg H, et al: Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 107(2), 2015
Fleming ND, Nick AM, Coleman RL, et al: Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer. Obstet Gynecol 132(3):545, 2018
Friebel TM, Domchek SM, Rebbeck TR: Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju091, 2014
Fruscio R, Ceppi L, Corso S, et al: Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer 115(6):641, 2016
Garcia C, Lyon L, Littell RD, et al: Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations. Genet Med 16(12):896, 2014
Gershenson DM, Bodurka DC, Coleman RL, et al: Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 35(10):1103, 2017
Goff BA, Mandel L, Muntz HG, et al: Ovarian carcinoma diagnosis. Cancer 89:2068, 2000
Goff BA, Mandel LS, Melancon CH, et al: Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705, 2004
Goff BA, Matthews BJ, Wynn M, et al: Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol 103:383, 2006
Grabowski JP, Harter P, Hils R, et al: Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer. Gynecol Oncol 126(1):54, 2012
Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101, 1975
Guseh SH, Rauh-Hain JA, Tambouret RH, et al: Transitional cell carcinoma of the ovary: a case-control study. Gynecol Oncol 132(3):649, 2014
Hannibal CG, Vang R, Junge J, et al: A nationwide study of serous “borderline” ovarian tumors in Denmark 1978–2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol 134(2):267, 2014
Harter P, Bois A, Hahmann M, et al: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 13:1702, 2006
Harter P, Gershenson D, Lhomme C, et al: Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 24(9 Suppl 3):S5, 2014
Harter P, Sehouli J, Lorusso D, et al: A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380(9):822, 2019
Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. In FIGO annual report on the results of treatment in gynaecological cancer. Int J Obstet Gynecol 95(Suppl 1):S161, 2006
Hinkula M, Pukkala E, Kyyronen P, et al: Incidence of ovarian cancer of grand multiparous women: a population-based study in Finland. Gynecol Oncol 103:207, 2006
Hurteau JA, Brady MF, Darcy KM, et al: Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group study. Gynecol Oncol 119:444, 2010
Huusom LD, Frederiksen K, Hogdall EV, et al: Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control 17:821, 2006
Im SS, Gordon AN, Buttin BM, et al: Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 105:35, 2005
Iodice S, Barile M, Rotmensz N, et al: Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 46(12):2275, 2010
Jacobs I, Oram D, Fairbanks J, et al: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG 97(10):922, 1990
Jacobs IJ, Menon U, Ryan A, et al: Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 387(10022):945, 2016
Jareid M, Thalabard JC, Aarflot M, et al: Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol 149(1):127, 2018
Jelinic P, Mueller JJ, Olvera N, et al: Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 46(5):424, 2014
Juretzka MM, Barakat RR, Chi DS, et al: CA-125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 104(1):176, 2007
Karlsen MA, Sandhu N, H?gdall C, et al: Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 127(2):379, 2012
Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet 374:1331, 2009
Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609, 2002
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 Mutation. J Clin Oncol 33(3):244, 2015
Kehoe S, Hook J, Nankivell M, et al: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249, 2015
Kiani F, Knutsen S, Singh P, et al: Dietary risk factors for ovarian cancer: the Adventist Health Study (United States). Cancer Causes Control 17:137, 2006
Kramer JL, Velazquez IA, Chen BE, et al: Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23:8629, 2005
Kristensen GS, Schledermann D, Mogensen O, et al: The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. Int J Gynecol Cancer 24(5):874, 2014
Kroeger PT Jr, Drapkin R: Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29(1):26, 2017
Kruitwagen RF, Swinkels BM, Keyser KG, et al: Incidence and effect on survival of abdominal wall metastases at trocar or puncture sites following laparoscopy or paracentesis in women with ovarian cancer. Gynecol Oncol 60:233, 1996
Kurman RJ, Carcangiu ML, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon, International Agency for Research on Cancer, 2014
Kurman RJ, Shih IM: The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186(4):733, 2016
Labidi-Galy SI, Papp E, Hallberg D, et al: High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8(1):1093, 2017
Lacour RA, Westin SN, Meyer LA, et al: Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121:358, 2011
Lancaster JM, Powell CB, Chen LM, et al: Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 136(1):3, 2015
Leary A, Petrella MC, Pautier P, et al: Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants. Gynecol Oncol 132(1):23, 2014
Lee AW, Ness RB, Roman LD, et al: Association between menopausal estrogen-only therapy and ovarian carcinoma risk. Ovarian cancer association consortium. Obstet Gynecol 127(5):828, 2016
Lee JY, Kim HS, Chung HH, et al: The role of omentectomy and random peritoneal biopsies as part of comprehensive surgical staging in apparent early-stage epithelial ovarian cancer. Ann Surg Oncol 21(8):2762, 2014
Lee KR, Tavassoli FA, Prat J, et al: Tumours of the ovary and peritoneum [Surface epithelial-stromal tumours]. In Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours. Geneva, WHO, 2003, p 117
Lessard-Anderson CR, Handlogten KS, Molitor RJ, et al: Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol 135(3):423, 2014
Levanon K, Crum C, Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26:5284, 2008Li AJ, Madden AC, Cass I, et al: The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92:211, 2004 Lin PS, Gershenson DM, Bevers MW, et al: The current status of surgical staging of ovarian serous borderline tumors. Cancer 85:905, 1999 Madalinska JB, Hollenstein J, Bleiker E, et al: Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890, 2005
Manchanda R, Abdelraheim A, Johnson M, et al: Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 118(7):814, 2011
Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001, 2001
Markman M, Liu PY, Moon J, et al: Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2 ) administered to patients with advanced ovarian cancer who attained a complete response to primary platinumpaclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase III trial. Gynecol Oncol 114(2):195, 2009
Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460, 2003
McCann CK, Growdon WB, Munro EG, et al: Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Ann Surg Oncol 18(10):2912, 2011
Melamed A, Nitecki R, Boruta DM II, et al: Laparoscopy compared with laparotomy for debulking ovarian cancer after neoadjuvant chemotherapy. Obstet Gynecol 129(5):861, 2017
Menzin AW, Gal D, Lovecchio JL: Contemporary surgical management of borderline ovarian tumors: a survey of the Society of Gynecologic Oncologists. Gynecol Oncol 78:7, 2000
Mercado C, Zingmond D, Karlan BY, et al: Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol 117:18, 2010
Mok SC, Schorge JO, Welch WR, et al: Tumours of the ovary and peritoneum [Peritoneal tumours]. In Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours. Geneva, WHO, 2003, p 197
Moore K, Colombo N, Scambia G: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495, 2018
Moore RG, Jabre-Raughley M, Brown AK, et al: Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203(3):228.e1, 2010
Moore RG, McMeekin DS, Brown AK, et al: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40, 2009
Moorman PG, Havrilesky LJ, Gierisch JM, et al: Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and metaanalysis. J Clin Oncol 31(33):4188, 2013
Morch LS, Skovlund CW, Hannaford PC, et al: Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377(23):2228, 2017
Morice P, Uzan C, Fauvet R, et al: Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 13(3):e103, 2012
National Cancer Institute: National Cancer Institute issues clinical announcement for preferred method of treatment for advanced ovarian cancer. 2006. Available at: https://www.nih.gov/news-events/news-releases/nci-issuesclinical-announcement-preferred-method-treatment-advanced-ovarian-cancer. Accessed August 12, 2019
National Cancer Institute: Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ®)–Health Professional Version. 2019. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelialtreatment-pdq. Accessed August 12, 2019
Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194, 2003
Park JY, Kim DY, Kim JH, et al: Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol 113:75, 2009
Park JY, Song JS, Choi G, et al: Pure primary squamous cell carcinoma of the ovary: a report of two cases and review of the literature. Int J Gynecol Pathol 29:328, 2010
Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099, 2003
Pecorelli S, Benedet JL, Creasman WT, et al: FIGO staging of gynecologic cancer, 1994–1997. FIGO Committee on Gynecologic Oncology, International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 65:243, 1999
Pelucchi C, Galeone C, Talamini R, et al: Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 196(1):83. e1, 2007
Penninkilampi R, Eslick GD: Perineal talc use and ovarian cancer: a systematic review and meta-analysis. Epidemiology 29(1):41, 2018
Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484, 2011
Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699, 2006
Pins MR, Young RH, Daly WJ, et al: Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol 20:823, 1996 Poncelet C, Fauvet R, Boccara J, et al: Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol 13:565, 2006
Pothuri B, Meyer L, Gerardi M, et al: Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol 95:193, 2004
Prat J, FIGO Committee on Gynecologic Oncology: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1, 2014
Prat J, Morice P: Tumours of the ovary and peritoneum [Secondary tumours of the ovary]. In Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours. Geneva, WHO, 2003, p 193
Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302, 2014
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323, 2010
Purdie DM, Bain CJ, Siskind V, et al: Ovulation and risk of epithelial ovarian cancer. Int J Cancer 104:228, 2003
Rao GG, Skinner E, Gehrig PA, et al: Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 104:261, 2004
Rao GG, Skinner EN, Gehrig PA, et al: Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 98:263, 2005
Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616, 2002
Rice MS, Hankinson SE, Tworoger SS: Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses’ Health Studies. Fertil Steril 102(1):192, 2014
Ring KL, Garcia C, Thomas MH, et al: Current and future role of genetic screening in gynecologic malignancies. Am J Obstet Gynecol 217(5): 512, 2017
Ronnett BM, Shmookler BM, Sugarbaker PH, et al: Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 2197, 1997
Ronnett BM, Yan H, Kurman RJ, et al: Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85, 2001
Rossing MA, Tang MT, Flagg EW, et al: A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 160:1070, 2004
Rustin GJ, van der Burg ME, Griffin CL, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomized trial. Lancet 376:1155, 2010
Schilder JM, Thompson AM, DePriest PD, et al: Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 87:1, 2002
Schildkraut JM, Bastos E, Berchuck A: Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89:932, 1997
Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261, 2006
Schorge JO, Clark RM, Lee SI, et al: Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? Gynecol Oncol 135(3):595, 2014
Schorge JO, Muto MG, Welch WR, et al: Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90:841, 1998
Schorge JO, Wingo SN, Bhore R, et al: Secondary cytoreductive surgery for platinum-sensitive ovarian cancer. Int J Gynaecol Obstet 108:123, 2010
Seidman JD, Kurman RJ: Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539, 2000
Shah JS, Mackelvie M, Gershenson DM, et al: Accuracy of intraoperative frozen section diagnosis of borderline ovarian tumors by hospital type. J Minim Invasive Gynecol 26(1):87, 2019
Sherman ME, Piedmonte M, Mai PL, et al: Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32(29):3275, 2014
Shih KK, Zhou QC, Aghajanian C, et al: Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol 119:270, 2010
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69(1):7, 2019
Silva EG, Gershenson DM, Malpica A, et al: The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 30:1367, 2006
Silva EG, Tornos C, Bailey MA, et al: Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med 115:377, 1991
Skates SJ, Greene MH, Buys SS, et al: Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk-combined results from two screening trials. Clin Cancer Res 23(14):3628, 2017
Skates SJ, Menon U, MacDonald N, et al: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21:206, 2003
Soliman PT, Slomovitz BM, Broaddus RR, et al: Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94:456, 2004
Suh-Burgmann E, Flanagan T, Osinski T, et al: Prospective validation of a standardized ultrasonography-based ovarian cancer risk assessment system. Obstet Gynecol 132(5):1101, 2018
Suidan RS, Ramirez PT, Sarasohn DM, et al: A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 134(3):455, 2014
Sutton GP, Bundy BN, Omura GA, et al: Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy: a Gynecologic Oncology Group study. Gynecol Oncol 41:230, 1991
Tang M, O’Connell RL, Amant F, et al: PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecol Oncol 154(3):531, 2019
Tewari KS, Burger RA, Enserro D, et al: Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37(26):2317, 2019
The ICON Collaborators: ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet 352:1571, 1998
The ICON Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505, 2002
Timmers PJ, Zwinderman K, Coens C, et al: Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer. Int J Gynecol Cancer 20:1142, 2010
Timofeev J, Galgano MT, Stoler MH, et al: Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol 116:1348, 2010
Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65(2):87, 2015
Torre LA, Islami F, Siegel RL, et al: Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 26(4):444, 2017
Torre LA, Trabert B, DeSantis CE, et al: Ovarian cancer statistics, 2018. CA Cancer J Clin. 68(4):284, 2018
Tozzi R, Kohler C, Ferrara A, et al: Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol 93:199, 2004
Trimble CL, Kosary C, Trimble EL: Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 86:34, 2002
Ueland FR, Desmone CP, Seamon LG, et al: Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 117(6):1289, 2011
U.S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC: Screening for gynecologic conditions with pelvic examination: US Preventive Services Task Force recommendation statement. JAMA 317(9):947, 2017
U.S. Preventive Services Task Force, Grossman DC, Curry SJ, et al: Screening for ovarian cancer: US recommendation statement. US Preventive Services Task Force. JAMA 319(6):588, 2018
van Driel WJ, Koole SN, Sikorska K, et al: Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230, 2018
Vergote I, Trope CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943, 2010
Verheijen RH, Mensdorff-Pouilly S, van Kamp GJ, et al: CA-125: fundamental and clinical aspects. Semin Cancer Biol 9:117, 1999
Vyarvelska I, Rosen B, Narod SA: Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers? Gynecol Oncol 134(2):219, 2014
Walker JL, Armstrong DK, Huang HQ, et al: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:27, 2006
Walker JL, Brady MF, Wenzel L, et al: Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 37(16):1380, 2019
Walker JL, Powell CB, Chen LM, et al: Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121(13):2108, 2015
Ware Miller R, Smith A, DeSimone CP, et al: Performance of the American College of Obstetricians and Gynecologists’ ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 117(6):1298, 2011
Wimberger P, Lehmann N, Kimmig R, et al: Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of AGOOVAR. Gynecol Oncol 106:69, 2007
Wingo SN, Knowles LM, Carrick KS, et al: Retrospective cohort study of surgical staging for ovarian low malignant potential tumors. Am J Obstet Gynecol 194:e20, 2006
Winter WE 3rd, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(24):3621, 2007
Yen ML, Yen BL, Bai CH, et al: Risk factors for ovarian cancer in Taiwan: a case-control study in a low-incidence population. Gynecol Oncol 89:318, 2003
Young RH, Oliva E, Scully RE: Small cell carcinoma of the ovary, hypercalcemic type: a clinicopathological analysis of 150 cases. Am J Surg Pathol 18:1102, 1994
Zaino RJ, Brady MF, Lele SM, et al: Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 117:554, 2011
Zapardiel I, Rosenberg P, Peiretti M, et al: The role of restaging borderline ovarian tumors: single institution experience and review of the literature. Gynecol Oncol 119:274, 2010
Zhang M, Lee AH, Binns CW: Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol 92:320, 2004
Zhang Z, Chan DW: The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 19(12):2995, 2010
American College of Obstetricians and Gynecologists: Uterine morcellation for presumed leiomyomas. Committee Opinion No. 770, March 2019
Bansal N, Herzog TJ, Burke W, et al: The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 110(1):43, 2008
Bell SW, Kempson RL, Hendrickson MR: Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 18(6):535, 1994
Brooks SE, Zhan M, Cote T, et al: Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93(1):204, 2004
Burke C, Hickey K: Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol 104(5 Pt 2):1182, 2004
Chan JK, Kawar NM, Shin JY, et al: Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 99:1210, 2008
Chu MC, Mor G, Lim C, et al: Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 90(1):170, 2003
Cui RR, Wright JD, Hou JY: Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. BJOG 124(7):1028, 2017
D’Angelo E, Prat J: Uterine sarcomas: a review. Gynecol Oncol 116:131, 2010
De Fusco PA, Gaffey TA, Malkasian GD Jr, et al: Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945–1980. Gynecol Oncol 35(1):8, 1989
DeMulder D, Ascher SM: Uterine leiomyosarcoma: can MRI differentiate leiomyosarcoma from benign leiomyoma before treatment? AJR Am J Roentgenol 211(6):1405, 2018
Dinh TA, Oliva EA, Fuller AF Jr, et al: The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 92:648, 2004
El-Rifai W, Sarlomo-Rikala M, Knuutila S, et al: DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. Am J Pathol 153(3):985, 1998
Felix AS, Cook LS, Gaudet MM, et al: The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer 108(3):727, 2013
Food and Drug Administration: Laparoscopic power morcellators. 2018. Available at: https://www.fda.gov/medical-devices/surgery-devices/laparoscopic-power-morcellators. Accessed April 5, 2019
Friedlander ML, Covens A, Glasspool RM, et al: Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract. Int J Gynecol Cancer 24(9 Suppl 3): S78, 2014
Gibault L, P?rot G, Chibon F, et al: New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol 223(1):64, 2011
Giuntoli RL, Garrett-Mayer E, Bristow RE, et al: Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 106(1):82, 2007
Gonzalez-Bosquet E, Martinez-Palones JM, Gonzalez-Bosquet J, et al: Uterine sarcoma: a clinicopathological study of 93 cases. Eur J Gynaecol Oncol 18(3):192, 1997
Greer BE, Koh WJ, Abu-Rustum NR, et al: Uterine neoplasms. NCCN Clinical Practice Guidelines in Oncology. Version 2. 2015. Available at: www.nccn.org/professionals/physician_gls/default.aspx#uterine. Accessed April 24, 2015
Halbwedl I, Ullmann R, Kremser ML, et al: Chromosomal alterations in lowgrade endometrial stromal sarcoma and undifferentiated endometrial sarcoma as detected by comparative genomic hybridization. Gynecol Oncol 97(2):582, 2005
Hensley ML, Blessing JA, Mannel R, et al: Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 109:329, 2008
Hensley ML, Enserro D, Hatcher H, et al: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 36(33):3324, 2018
Hensley ML, Miller DS, O’Malley DM, et al: Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/ Gynecologic Oncology Group study. J Clin Oncol 33(10):1180, 2015
Hinchcliff EM, Esselen KM, Watkins JC, et al: The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma. J Minim Invasive Gynecol 23(4):567, 2016
Hoang L, Chiang S, Lee CH: Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations. Pathology 50(2):162, 2018
Hosh M, Antar S, Nazzal A, et al: Uterine sarcoma: analysis of 13,089 cases based on Surveillance, Epidemiology, and End Results Database. Int J Gynecol Cancer 26(6):1098, 2016
Kapp DS, Shin JY, Chan JK: Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112(4):820, 2008
Kho KA, Lin K, Hechanova M, et al: Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. Obstet Gynecol 127(3):468, 2016
Koh WJ, Abu-Rustum NR, Bean S, et al: Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(2):170, 2018
Leath CA III, Huh WK, Hyde J Jr, et al: A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105:630, 2007
Leath CA III, Numnum TM, Kendrick JE, et al: Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer 19:888, 2009
Lee CH, Ou WB, Mari?o-Enriquez A, et al: 14-3-3 fusion oncogenes in highgrade endometrial stromal sarcoma. Proc Natl Acad Sci USA 109(3):929, 2012
Leibsohn S, d’Ablaing G, Mishell DR, et al: Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 162(4):968, 1990
Leunen M, Breugelmans M, De Sutter P, et al: Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 95(3):769, 2004
Lieng M, Berner E, Busund B: Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women. J Minim Invasive Gynecol 22(3):410, 2015
Lissoni A, Cormio G, Bonazzi C, et al: Fertility-sparing surgery in uterine leiomyosarcoma. Gynecol Oncol 70(3):348, 1998
Littell RD, Tucker LY, Raine-Bennett T, et al: Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes. Gynecol Oncol 147(1):11, 2017
Livi L, Paiar F, Shah N, et al: Uterine sarcoma: twenty-seven years of experience. Int J Radiat Oncol Biol Phys 57(5):1366, 2003
Machida H, Nathenson MJ, Takiuchi T, et al: Significance of lymph node metastasis on survival of women with uterine adenosarcoma. Gynecol Oncol 144(3):524, 2017
Major FJ, Blessing JA, Silverberg SG, et al: Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71(4 Suppl): 1702, 1993
Meurer M, Floquet A, Ray-Coquard I, et al: Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. Int J Gynecol Cancer 29(4):691, 2019
Micci F, Panagopoulos I, Bjerkehagen B, et al: Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res 66(1):107, 2006
Michener CM, Simon NL: Ovarian conservation in a woman of reproductive age with m?llerian adenosarcoma. Gynecol Oncol 83(2):424, 2001
Miller DS, Blessing JA, Kilgore LC, et al: Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study. Am J Clin Oncol 23(4):355, 2000
Multinu F, Casarin J, Tortorella L, et al: Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study. Am J Obstet Gynecol 220(2):179. e1, 2019
Nasioudis D, Ko EM, Kolovos G, et al: Ovarian preservation for low-grade endometrial stromal sarcoma: a systematic review of the literature and metaanalysis. Int J Gynecol Cancer 29(1):126, 2019
Nemani D, Mitra N, Guo M, et al: Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 111:82, 2008
Oliva E: Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol 33(4):374, 2014a
Oliva E, Carcangiu ML, Carinelli SG, et al: Mesenchymal tumours. In Kurman RJ, Carcangiu LM, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs. Lyon, International Agency for Research on Cancer, 2014b, p 135
Omura GA, Major FJ, Blessing JA, et al: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52(4):626, 1983
Panagopoulos I, Micci F, Thorsen J, et al: Novel fusion of MYST/ESA1- associated factor 6 and PHF1 in endometrial stromal sarcoma. PLoS One 7(6): e39354, 2012
Parker WH, Fu YS, Berek JS: Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 83(3):414, 1994
Perri T, Korach J, Sadetzki S, et al: Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer 19:257, 2009
Pink D, Lindner T, Mrozek A, et al: Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 101(3):464, 2006
Rauh-Hain JA, Goodman A, Boruta DM, et al: Endometrial stromal sarcoma: a clinicopathologic study of 29 patients. J Reprod Med 59(11-12):547, 2014
Reed NS, Mangioni C, Malmstrom H, et al: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 44:808, 2008
Reich O, Regauer S: Survey of adjuvant hormone therapy in patients after endometrial stromal sarcoma. Eur J Gynaecol Oncol 27(2):150, 2006
Salani R, Khanna N, Frimer M, et al: An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146(1):3, 2017
Seagle BL, Kanis M, Strohl AE, et al: Survival of women with mullerian adenosarcoma: a National Cancer Data Base study. Gynecol Oncol 143(3):636, 2016
Seagle BL, Shilpi A, Buchanan S, et al: Low-grade and high-grade endometrial stromal sarcoma: a National Cancer Database study. Gynecol Oncol 146(2):254, 2017a
Seagle BL, Sobecki-Rausch J, Strohl AE, et al: Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol 145(1):61, 2017b
Sharma P, Kumar R, Singh H, et al: Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging. Nucl Med Commun 33(2): 185, 2012
Sumi A, Terasaki H, Sanada S, et al: Assessment of MR imaging as a tool to differentiate between the major histological types of uterine sarcomas. Magn Reson Med Sci 14(4):295, 2015
Sutton GP, Stehman FB, Michael H, et al: Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol 68(5):709, 1986
Thomas MB, Keeney GL, Podratz KC, et al: Endometrial stromal sarcoma: treatment and patterns of recurrence. Int J Gynecol Cancer 19:253, 2009
Wells M, Oliva E, Palacios J, et al: Mixed epithelial and mesenchymal tumours. In Kurman RJ, Carcangiu LM, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs. Lyon, International Agency for Research on Cancer, 2014, p 148
Yan L, Tian Y, Zhao X: Successful pregnancy after fertility-preserving surgery for endometrial stromal sarcoma. Fertil Steril 93:269. e1, 2010
Yang GC, Wan LS, Del Priore G: Factors influencing the detection of uterine cancer by suction curettage and endometrial brushing. J Reprod Med 47(12):1005, 2002
Zaloudek C, Hendrickson MR, Soslow RA: Mesenchymal tumors of the uterus. In Kurman RJ, Ellenson LH, Ronnett BM (eds): Blaustein’s Pathology of the Female Genital Tract, 6th ed. New York, Springer, 2011, p 453
Zhang P, Zhang C, Hao J, et al: Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma. Hum Pathol 37(10):1350, 2006
Aalders J, Abeler V, Kolstad P, et al: s. Obstet Gynecol 56(4):419, 1980
Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214, 1999
Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N, et al: Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol 113(2):163, 2009
Ahluwalia M, Light AM, Surampudi K, et al: Transitional cell carcinoma of the endometrium: a case report and review of the literature. Int J Gynecol Pathol 25(4):378, 2006
Allison KH, Reed SD, Voigt LF, et al: Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 32(5):691, 2008
Altman AD, Thompson J, Nelson G, et al: Use of aromatase inhibitors as firstand second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J Obstet Gynaecol Can 34(7):664, 2012
Altrabulsi B, Malpica A, Deavers MT, et al: Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 29(10):1316, 2005
American College of Obstetricians and Gynecologists: Diagnosis of abnormal uterine bleeding in reproductive-aged women. Practice Bulletin No. 128, July 2012, Reaffirmed 2016
American College of Obstetricians and Gynecologists: Endometrial intraepithelial neoplasia. Committee Opinion No. 631, May 2015, Reaffirmed 2017a
American College of Obstetricians and Gynecologists: Management of endometrial cancer. Practice Bulletin No. 149, April 2015a, Reaffirmed 2017b
American College of Obstetricians and Gynecologists: Hysteroscopy. Technology Assessment No. 13, May 2018a
American College of Obstetricians and Gynecologists: The role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Committee Opinion No. 734, May 2018b
American College of Obstetricians and Gynecologists: Lynch syndrome. Practice Bulletin No. 147, November 2014a, Reaffirmed 2019a
American College of Obstetricians and Gynecologists: Opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. Committee Opinion No. 774, March 2019b
American College of Obstetricians and Gynecologists: Tamoxifen and uterine cancer. Committee Opinion No. 601, June 2014b, Reaffirmed 2019c
American Joint Committee on Cancer: AJCC Cancer Staging Manual, 7th ed. Chicago, American Joint Committee on Cancer, 2010, p 408
Anastasiadis PG, Skaphida PG, Koutlaki NG, et al: Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol 21(2):131, 2000
Ashfaq R, Sharma S, Dulley T, et al: Clinical relevance of benign endometrial cells in postmenopausal women. Diagn Cytopathol 25(4):235, 2001
Awtrey CS, Cadungog MG, Leitao MM, et al: Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 102(3):480, 2006
Baak JP, Mutter GL, Robboy S, et al: The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994
World Health Organization classification system. Cancer 103(11):2304, 2005
Ballester M, Dubernard G, L?curu F, et al: Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 12(5):469, 2011
Bansal N, Yendluri V, Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16(1):8, 2009
Barakat RR, Bundy BN, Spirtos NM, et al: Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 24(4):587, 2006
Barakat RR, Goldman NA, Patel DA, et al: Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 75(1):99, 1999
Barrena Medel NI, Bansal S, Miller DS, et al: Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother 10(12):1939, 2009
Bellone S, Eliana B, Lonardi S, et al: Polymerase ? (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol 144(1):146, 2017
Ben Yehuda OM, Kim YB, Leuchter RS: Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 68:4, 1998
Benedetti Panici P, Basile S, Maneschi F, et al: Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707, 2008
Boronow RC, Morrow CP, Creasman WT, et al: Surgical staging in endometrial cancer: clinical–pathologic findings of a prospective study. Obstet Gynecol 63:825, 1984
Bosse T, Peters EE, Creutzberg CL, et al: Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 51(13):1742, 2015
Breitkopf DM, Frederickson RA, Snyder RR: Detection of benign endometrial masses by endometrial stripe measurement in premenopausal women. Obstet Gynecol 104(1):2004
Bristow RE, Asrari F, Trimble EL, et al: Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I–III) disease. Gynecol Oncol 81(2):279, 2001a
Bristow RE, Duska LR, Montz FJ: The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 81(1):92, 2001b
Bristow RE, Purinton SC, Santillan A, et al: Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 103(2): 709, 2006a
Bristow RE, Santillan A, Zahurak ML, et al: Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol 103(1):281, 2006b
Bristow RE, Zerbe MJ, Rosenshein NB, et al: Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78(2):85, 2000
Burke TW, Levenback C, Tornos C, et al: Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol 62(2):169, 1996
Burke WM, Orr J, Leitao M, et al: Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 134(2):393, 2014
Cannon GM, Geye H, Terakedis BE, et al: Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma. Gynecol Oncol 113(2):176, 2009
Carcangiu ML, Chambers JT: Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 47(3):298, 1992
Chan JK, Loizzi V, Youssef M, et al: Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 90(1):181, 2003
Chan JK, Sherman AE, Kapp DS, et al: Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 29(7):832, 2011
Chao CK, Grigsby PW, Perez CA, et al: Medically inoperable stage I endometrial carcinoma: a few dilemmas in radiotherapeutic management. Int J Radiat Oncol Biol Phys 34(1):27, 1996
Childers JM, Spirtos NM, Brainard P, et al: Laparoscopic staging of the patient with incompletely staged early adenocarcinoma of the endometrium. Obstet Gynecol 83(4):597, 1994
Cicinelli E, Tinelli R, Colafiglio G, et al: Risk of long-term pelvic recurrences after fluid minihysteroscopy in women with endometrial carcinoma: a controlled randomized study. Menopause 17(3):511, 2010
Clarke MA, Long BJ, Del Mar Morillo A, et al: Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med 178(9):1210, 2018
Cooper AL, Dornfeld-Finke JM, Banks HW, et al: Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer? Obstet Gynecol 107(1):71, 2006
Cornelison TL, Trimble EL, Kosary CL: SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988–1994. Gynecol Oncol 74(3):350, 1999
Creasman W, Odicino F, Maisonneuve P, et al: Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(suppl 1):S105, 2006
Creutzberg CL, van Putten WL, Koper PC, et al: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Postoperative radiation therapy in endometrial carcinoma. Lancet 355(9213):1404, 2000
Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, et al: Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22(7):1234, 2004
de Boer SM, Powell ME, Mileshkin LR, et al: Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer. J Clin Oncol 35(15 suppl):5502, 2017
Delin JB, Miller DS, Coleman RL: Other primary malignancies in patients with uterine corpus malignancy. Am J Obstet Gynecol 190:1429, 2004
Dhar KK, NeedhiRajan T, Koslowski M, et al: Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 97(3):924, 2005
Dietrich CS III, Modesitt SC, DePriest PD, et al: The efficacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol 99(3):557, 2005
Dossus L, Allen N, Kaaks R, et al: Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 127(2):442, 2010
Ellenson LH, Ronnett BM, Kurman RJ: Precursor lesions of endometrial carcinoma. In Kurman RJ, Ellenson LH, Ronnett BM (eds): Blaustein’s Pathology of the Female Genital Tract, New York, Springer, 2011a, p 360
Ellenson LH, Ronnett BM, Soslow RA: Endometrial cancer. In Kurman RJ, Ellenson LH, Ronnett BM (eds): Blaustein’s Pathology of the Female Genital Tract, New York, Springer, 2011b, p 422
Elshaikh MA, Al-Wahab Z, Mahdi H, et al: Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multiinstitution study. Gynecol Oncol 136(2):235, 2015
Eltabbakh GH, Shamonki J, Mount SL: Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol 99(2):309, 2005
Fader AN, Roque DM, Siegel E, et al: Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 36(20):2044, 2018
Fearnley EJ, Marquart L, Spurdle AB, et al: Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control 12:2303, 2010
Feldman S, Berkowitz RS, Tosteson AN: Cost-effectiveness of strategies to evaluate postmenopausal bleeding. Obstet Gynecol 81(6):968, 1993
Felix AS, Gaudet MM, La Vecchia C, et al: Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer 136(5):E410, 2015
Felix AS, Weissfeld JL, Stone RA, et al: Factors associated with type I and type II endometrial cancer. Cancer Causes Control 21(11):1851, 2010
Feltmate CM, Duska LR, Chang Y, et al: Predictors of recurrence in surgical stage II endometrial adenocarcinoma. Gynecol Oncol 73(3):407, 1999
Ferrandina G, Zannoni GF, Gallotta V, et al: Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol 99(1):215, 2005
FIGO Committee on Gynecologic Oncology: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105(2):103, 2009
Fiorica JV, Brunetto VL, Hanjani P, et al: Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92(1):10, 2004
Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371, 1998
Fishman DA, Roberts KB, Chambers JT, et al: Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 61(2):189, 1996
Fleming GF, Brunetto VL, Cella D, et al: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22(11):2159, 2004
Frumovitz M, Singh DK, Meyer L, et al: Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 95(3):463, 2004a
Frumovitz M, Slomovitz BM, Singh DK, et al: Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg 199(3):388, 2004b
Galaal K, van der Heijden E, Godfrey K, et al: Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2:CD006812, 2013
Gallos ID, Shehmar M, Thangaratinam S, et al: Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 203(6):547.e1, 2010
Garuti G, Mirra M, Luerti M: Hysteroscopic view in atypical endometrial hyperplasias: a correlation with pathologic findings on hysterectomy specimens. J Minim Invasive Gynecol 13(4):325, 2006
Gehrig PA, Groben PA, Fowler WC Jr, et al: Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol 97(1):153, 2001
Ghezzi F, Cromi A, Uccella S, et al: Laparoscopic versus open surgery for endometrial cancer: a minimum 3-year follow-up study. Ann Surg Oncol 17(1):271, 2010
Goldstein SR, Zeltser I, Horan CK, et al: Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 177(1):102, 1997
Goodman A, Zukerberg LR, Rice LW, et al: Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol 61(1):54, 1996
Gotlieb WH, Beiner ME, Shalmon B, et al: Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 102(4):718, 2003
Graebe K, Garcia-Soto A, Aziz M, et al: Incidental power morcellation of malignancy: a retrospective cohort study. Gynecol Oncol 136(2):274, 2015
Granberg S, Wikland M, Karlsson B, et al: Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 164:47, 1991
Grice J, Ek M, Greer B, et al: Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 69(1):69, 1998
Hamilton CA, Cheung MK, Osann K, et al: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5):642, 2006
Haruma T, Nagasaka T, Nakamura K, et al: Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. PLoS ONE 13(4):e0195655, 2018
Havrilesky LJ, Cragun JM, Calingaert B, et al: Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol 99(3):689, 2005
Hecht JL, Ince TA, Baak JP, et al: Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 18(3):324, 2005
Hemminki K, Bermejo JL, Granstrom C: Endometrial cancer: population attributable risks from reproductive, familial and socioeconomic factors. Eur J Cancer 41(14):2155, 2005
Hirai Y, Takeshima N, Kato T, et al: Malignant potential of positive peritoneal cytology in endometrial cancer. Obstet Gynecol 97(5 Pt 1):725, 2001
Hoekstra AV, Jairam-Thodla A, Rademaker A, et al: The impact of robotics on practice management of endometrial cancer: transitioning from traditional surgery. Int J Med Robot 5(4):392, 2009
Holloway RM, Abu-Rustum NR, Backes FJ, et al: Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecologic Oncology 146(2):405, 2017
Homesley HD, Filiaci V, Markman M, et al: Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol 25(5):526, 2007
Homesley HD, Filiaci V, Gibbons SK et al: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 112:543, 2009
Horn LC, Schnurrbusch U, Bilek K, et al: Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14(2):348, 2004
Hoskins PJ, Swenerton KD, Pike JA, et al: Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19(20):4048, 2001
Huh WK, Powell M, Leath CA III, et al: Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 91(3):470, 2003
Jacobs I, Gentry-Maharaj A, Burnell M, et al: Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a casecontrol study within the UKCTOCS cohort. Lancet Oncol 12(1):38, 2011
Janda M, Gebski V, Davies LC, et al: Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 317(12):1224, 2017
Jordan LB, Abdul-Kader M, Al Nafussi A: Uterine serous papillary carcinoma: histopathologic changes within the female genital tract. Int J Gynecol Cancer 11(4):283, 2001
Kandoth C, Schultz N, Cherniack AD: Integrated genomic characterization of endometrial carcinoma. Nature 497:67, 2013
Kelly MG, O’Malley DM, Hui P, et al: Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 98(3):353, 2005
Keys HM, Roberts JA, Brunetto VL, et al: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92(3):744, 2004
Kilgore LC, Partridge EE, Alvarez RD, et al: Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56(1):29, 1995
Kim YB, Holschneider CH, Ghosh K, et al: Progestin alone as primary treatment of endometrial carcinoma in premenopausal women: report of seven cases and review of the literature. Cancer 79(2):320, 1997
King LP, Miller DS: Recent progress: Gynecologic Oncology Group trials in uterine corpus tumors. Rev Recent Clin Trials 4(2):70, 2009
Kitchener H, Swart AM, Qian Q, et al: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet 373:125, 2009
Kornblith AB, Huang HQ, Walker JL, et al: Quality of life of patients with endometrial cancer undergoing laparoscopic International Federation of Gynecology and Obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol 27(32):5337, 2009
Kurman RJ, Carcangiu ML, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon, International Agency for Research on Cancer, 2014
Kurman RJ, Kaminski PF, Norris HJ: The behavior of endometrial hyperplasia. A long-term study of «untreated» hyperplasia in 170 patients. Cancer 56(2):403, 1985
Kurman RJ, Norris HJ: Endometrial hyperplasia and related cellular changes. In Kurman RJ (ed): Blaustein’s Pathology of the Female Genital Tract. 1994, p 411
Lancaster JM, Powell CB, Chen LM, et al: Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 136(1):3, 2015
Leitao MM, Kehoe S, Barakat RR, et al: Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 111:244, 2008
Lentz SS, Brady MF, Major FJ, et al: High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 14(2):357, 1996
Lurain JR, Rice BL, Rademaker AW, et al: Prognostic factors associated with disease recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 78:63, 1991
Madison T, Schottenfeld D, James SA, et al: Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health 94(12):2104, 2004
Magrina JF, Mutone NF, Weaver AL, et al: Laparoscopic lymphadenectomy and vaginal or laparoscopic hysterectomy with bilateral salpingo-oophorectomy for endometrial cancer: morbidity and survival. Am J Obstet Gynecol 181(2):376, 1999
Major FJ, Blessing JA, Silverberg SG, et al: Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71(4 Suppl):1702, 1993
Mariani A, Webb MJ, Keeney GL, et al: Hematogenous dissemination in corpus cancer. Gynecol Oncol 80(2):233, 2001a
Mariani A, Webb MJ, Keeney GL, et al: Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol 83(1):72, 2001b
Martin JD, Gilks B, Lim P: Papillary serous carcinoma—a less radio-sensitive subtype of endometrial cancer. Gynecol Oncol 98(2):299, 2005
Martonez A, Querleu D, Leblanc E, et al: Low incidence of port-site metastases after laparoscopic staging of uterine cancer. Gynecol Oncol 118(2):145, 2010
Matei D, Filiaci VL, Randall M, et al: A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol 35(15 suppl):5505, 2017
Maxwell GL, Schildkraut JM, Calingaert B, et al: Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 103(2):535, 2006
Melhem MF, Tobon H: Mucinous adenocarcinoma of the endometrium: a clinico-pathological review of 18 cases. Int J Gynecol Pathol 6(4):347, 1987
Miller D, Filiaci V, Fleming G, et al: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125(3):771, 2012
Miller DS, Fleming G, Randall ME: Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer. J Natl Compr Cancer Netw 7(5):535, 2009
Moller KA, Gehrig PA, Van Le L, et al: The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 94(1):170, 2004
Montz FJ, Bristow RE, Bovicelli A, et al: Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 186(4):651, 2002
Morimoto LM, Newcomb PA, Hampton JM, et al: Cholecystectomy and endometrial cancer: a marker of long-term elevated estrogen exposure? Int J Gynecol Cancer 16(3):1348, 2006
Morris M, Alvarez RD, Kinney WK, et al: Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 60(2):288, 1996
Morrow CP, Bundy BN, Kurman RJ, et al: Relationship between surgicalpathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40(1):55, 1991
Mount SL, Wegner EK, Eltabbakh GH, et al: Significant increase of benign endometrial cells on Papanicolaou smears in women using hormone replacement therapy. Obstet Gynecol 100(3):445, 2002
Mutter GL: Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 76(3):287, 2000
Nagar H, Dobbs S, McClelland HR, et al: The diagnostic accuracy of magnetic resonance imaging in detecting cervical involvement in endometrial cancer. Gynecol Oncol 103(2):431, 2006
National Comprehensive Cancer Network: Uterine neoplasms, version 3.2019. Plymouth Meeting, National Comprehensive Cancer Network, 2019
Nemani D, Mitra N, Guo M, et al: Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 111:82, 2008
Nevadunsky NS, Van Arsdale A, Strickler HD, et al: Obesity and age at diagnosis of endometrial cancer. Obstet Gynecol 124(2 Pt 1):300, 2014
Niwa K, Tagami K, Lian Z, et al: Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 112(3):317, 2005
Nout RA, Smit VT, Putter H, et al: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375(9717):816, 2010
Obermair A, Geramou M, Gucer F, et al: Does hysteroscopy facilitate tumor cell dissemination? Incidence of peritoneal cytology from patients with early stage endometrial carcinoma following dilatation and curettage (D & C) versus hysteroscopy and D & C. Cancer 88(1):139, 2000
Onda T, Yoshikawa H, Mizutani K, et al: Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 75:1836, 1997
Orbo A, Vereide A, Arnes M, et al: Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 121(4):477, 2014
Ott PA, Bang YJ, Berton-Rigaud D, et al: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 35(22):2535, 2017
Papadia A, Azioni G, Brusaca B, et al: Frozen section underestimates the need for surgical staging in endometrial cancer patients. Int J Gynecol Cancer 19(9):1570, 2009
Park JY, Kim DY, Kim JH, et al: The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol 17:861, 2010
Pecorelli S, Benedet JL, Creasman WT, et al: FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 64(1):5, 1999
Pillay OC, Te Fong LF, Crow JC, et al: The association between polycystic ovaries and endometrial cancer. Hum Reprod 21(4):924, 2006
Polyzos NP, Mauri D, Tsioras S, et al: Intraperitoneal dissemination of endometrial cancer cells after hysteroscopy: a systematic review and meta-analysis. Int J Gynecol Cancer 20(2):261, 2010
Powell JL, Hill KA, Shiro BC, et al: Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 50(8):585, 2005
Powell MA, Filiaci VL, Rose PG, et al: Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol 28(16):2727, 2010
Price FV, Chambers SK, Carcangiu ML, et al: CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer 82(9):1720, 1998
Provenzale D, Gupta S, Ahnen DJ, et al: NCCN guidelines insights: colorectal cancer screening, version 1.2018. J Natl Compr Canc Netw 16(8):939, 2018
Randall ME, Filiaci VL, Muss H, et al: Randomized phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 24(1):36, 2006
Randall TC, Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90(3):434, 1997
Rattanachaiyanont M, Angsuwathana S, Techatrisak K, et al: Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. J Obstet Gynaecol Res 31(2):98, 2005
Reed NS, Mangioni C, Malmstrom H, et al: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 44:808, 2008
Reed SD, Voigt LF, Newton KM, et al: Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 113(3):655, 2009
Resnick KE, Hampel H, Fishel R, et al: Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 114(1):128, 2009
Revel A, Tsafrir A, Anteby SO, et al: Does hysteroscopy produce intraperitoneal spread of endometrial cancer cells? Obstet Gynecol Surv 59:280, 2004
Ricci E, Moroni S, Parazzini F, et al: Risk factors for endometrial hyperplasia: results from a case-control study. Int J Gynecol Cancer 12(3):257, 2002
Rittenberg PV, Lotocki RJ, Heywood MS, et al: Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in nodenegative tumors. Gynecol Oncol 98(3):434, 2005
Roland PY, Kelly FJ, Kulwicki CY, et al: The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment. Gynecol Oncol 93(1):125, 2004
Ross JC, Eifel PJ, Cox RS, et al: Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol 7(8):715, 1983
Rossi EC, Kowalski LD, Scalici J, et al: A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18(3):384, 2017
Rubatt JM, Slomovitz BM, Burke TW, et al: Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol 99(2):472, 2005
Salani R, Khanna N, Frimer M et al: An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology recommendations. Gynecol Oncol 146:3, 2017
Sanjuan A, Cobo T, Pahisa J, et al: Preoperative and intraoperative assessment of myometrial invasion and histologic grade in endometrial cancer: role of magnetic resonance imaging and frozen section. Int J Gynecol Cancer 16(1):385, 2006
Sartori E, Bazzurini L, Gadducci A, et al: Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol 67:70, 1997
Scarselli G, Bargelli G, Taddei GL, et al: Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study. Fertil Steril 95(1):420, 2011
Schiavone MB, Scelzo C, Straight C, et al: Survival of patients with serous uterine carcinoma undergoing sentinel lymph node mapping. Ann Surg Oncol 24(7):1965, 2017
Schiavone MB, Zivanovic O, Zhou Q, et al: Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol 23(1):196, 2016
Schink JC, Rademaker AW, Miller DS, et al: Tumor size in endometrial cancer. Cancer 67(11):2791, 1991 Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261, 2006
Schottenfeld D: Epidemiology of endometrial neoplasia. J Cell Biochem Suppl 23:151, 1995 Seamon LG, Cohn DE, Henretta MS, et al: Minimally invasive comprehensive surgical staging for endometrial cancer: robotics or laparoscopy? Gynecol Oncol 113(1):36, 2009
Sherman ME, Bitterman P, Rosenshein NB, et al: Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 16(6):600, 1992
Sherman ME, Ronnett BM, Ioffe OB, et al: Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. Int J Gynecol Pathol 27(3):318, 2008
Shi AA, Lee SI: Radiological reasoning: algorithmic workup of abnormal vaginal bleeding with endovaginal sonography and sonohysterography. AJR Am J Roentgenol 191(6 Suppl):S68, 2008
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69(1):7, 2019
Silva EG, Deavers MT, Malpica A: Undifferentiated carcinoma of the endometrium: a review. Pathology 39(1):134, 2007
Simsir A, Carter W, Elgert P, et al: Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001. Am J Clin Pathol 123(4):571, 2005
Slomovitz BM, Burke TW, Eifel PJ, et al: Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91(3):463, 2003
Slomovitz BM, Jiang Y, Yates MS, et al: Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33(8):930, 2015
Smith DC, Prentice R, Thompson DJ, et al: Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293(23):1164, 1975
Smith RA, Andrews KS, Brooks D, et al: Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 69(3):184
Smith-Bindman R, Weiss E, Feldstein V: How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol 24(5):558, 2004
Soliman PT, Oh JC, Schmeler KM, et al: Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 105(3):575, 2005
Soliman PT, Westin SN, Dioun S, et al: A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146(2):234, 2017
Sovak MA, Dupont J, Hensley ML, et al: Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 17(1):197, 2007
Sovak MA, Hensley ML, Dupont J, et al: Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol 103(2):451, 2006
Spirtos NM, Eisekop SM, Boike G, et al: Laparoscopic staging in patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum: a Gynecologic Oncology Group (GOG) study. Am J Obstet Gynecol 193(5):1645, 2005
Stanford JL, Brinton LA, Berman ML, et al: Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 54(2):243, 1993
Strom BL, Schinnar R, Weber AL, et al: Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 164(8):775, 2006
Suh-Burgmann E, Hung YY, Armstrong MA: Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstet Gynecol 114(3):523, 2009
Suriano KA, McHale M, McLaren CE, et al: Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97(4):555, 2001
Surveillance, Epidemiology, and End Results Program: Cancer stat facts: uterine cancer. 2018.
Tao MH, Xu WH, Zheng W, et al: Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer 119(9):2142, 2006
Temkin SM, Hellmann M, Lee YC, et al: Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer 17:215, 2007
Terakawa N, Kigawa J, Taketani Y, et al: The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res 23(3):223, 1997
Thigpen JT, Brady MF, Alvarez RD, et al: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17(6):1736, 1999
Todo Y, Kato H, Kaneuchi M, et al: Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375(9721):1165, 2010
Trimble CL, Kauderer J, Zaino R, et al: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106(4):812, 2006
Trimble CL, Method M, Leitao M, et al: Management of endometrial precancers. Obstet Gynecol 120(5):1160, 2012
Vaidya AP, Horowitz NS, Oliva E, et al: Uterine malignant mixed m?llerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol 103:684, 2006
van Hanegem N, Breijer MC, Slockers SA, et al: Diagnostic workup for postmenopausal bleeding: a randomised controlled trial. BJOG 124(2):231, 2017
van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343(8895):448, 1994
Varras M, Kioses E: Five-year survival of a patient with primary endometrial squamous cell carcinoma: a case report and review of the literature. Eur J Gynaecol Oncol 23(4):327, 2002
Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116(6):1453, 1999
Viswanathan AN, Feskanich D, De Vivo I, et al: Smoking and the risk of endometrial cancer: results from the Nurses’ Health Study. Int J Cancer 114(6):996, 2005
Vorgias G, Hintipas E, Katsoulis M, et al: Intraoperative gross examination of myometrial invasion and cervical infiltration in patients with endometrial cancer: decision-making accuracy. Gynecol Oncol 85(3):483, 2002
Wada H, Enomoto T, Fujita M, et al: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 57(23):5379, 1997
Walker JL, Piedmonte MR, Spirtos NM, et al: Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study (LAP2). J Clin Oncol 27(32): 5331, 2009
Walker JL, Piedmonte MR, Spirtos NM, et al: Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 study. J Clin Oncol 30(7):695, 2012
Wang CB, Wang CJ, Huang HJ, et al: Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 94(8):2192, 2002
Wernli KJ, Ray RM, Gao DL, et al: Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women. Cancer Causes Control 17(7):949, 2006
Whitney CW, Brunetto VL, Zaino RJ, et al: Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92(1):4, 2004
Winder AA, Kularatna M, MacCormick AD: Does bariatric surgery affect the incidence of endometrial cancer development? A systematic review. Obes Surg 28(5):1433, 2018
Wolfman W, Leyland N, Heywood M, et al: Asymptomatic endometrial thickening. J Obstet Gynaecol Can 32(10):990, 2010
Wolfson AH, Brady MF, Rocereto T, et al: A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:177, 2007
Yang YC, Wu CC, Chen CP, et al: Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 99(2):287, 2005
Zaino RJ, Kauderer J, Trimble CL, et al: Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106(4):804, 2006
Zaino RJ, Kurman RJ, Diana KL, et al: The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75(1):81, 1995
Zaino RJ, Silverberg SG, Norris HJ, et al: The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol 13(1):29, 1994
Zerbe MJ, Zhang J, Bristow RE, et al: Retrograde seeding of malignant cells during hysteroscopy in presumed early endometrial cancer. Gynecol Oncol 79(1):55, 2000
Zullo F, Palomba S, Falbo A, et al: Laparoscopic surgery vs laparotomy for early stage endometrial cancer: long-term data of a randomized controlled trial. Am J Obstet Gynecol 200(3):296.e1, 2009
Ahram J, Lemus R, Schiavello HJ: Leiomyosarcoma of the vagina: case report and literature review. Int J Gynecol Cancer 16:884, 2006
Alemany L, Saunier M, Tinoco L, et al: Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 50(16):2846, 2014
Andrassy RJ, Hays DM, Raney RB, et al: Conservative surgical management of vaginal and vulvar pediatric rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study III. J Pediatr Surg 30:1034, 1995
Andrassy RJ, Wiener ES, Raney RB, et al: Progress in the surgical management of vaginal rhabdomyosarcoma: a 25-year review from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Surg 34:731, 1999
Beller U, Maisonneuve P, Benedet JL, et al: Carcinoma of the vagina. Int J Gynaecol Obstet 83 Suppl 1:27, 2003
Buchanan DJ, Schlaerth J, Kurosaki T: Primary vaginal melanoma: thirteenyear disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 178:1177, 1998
Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 395:2327, 2011
Chung HC, Schellens JH, Delord JP, et al: Pembrolizumab treatment of advanced cervical cancer. Updated results from the phase 2 KEYNOTE-158 study. J Clin Oncol 36(15 suppl):5522, 2018
Chyle V, Zagars GK, Wheeler JA, et al: Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 35: 891, 1996
Copeland LJ, Gershenson DM, Saul PB, et al: Sarcoma botryoides of the female genital tract. Obstet Gynecol 66:262, 1985
Creasman WT, Phillips JL, Menck HR: The National Cancer Data Base report on cancer of the vagina. Cancer 83:1033, 1998
Curtin JP, Saigo P, Slucher B, et al: Soft-tissue sarcoma of the vagina and vulva: a clinicopathologic study. Obstet Gynecol 86:269, 1995
Davis KP, Stanhope CR, Garton GR, et al: Invasive vaginal carcinoma: analysis of early-stage disease. Gynecol Oncol 42:131, 1991
FIGO Committee on Gynecologic Oncology: Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 105(1):3, 2009
Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694, 2012
Frank SJ, Deavers MT, Jhingran A, et al: Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecol Oncol 105:470, 2007
Frank SJ, Jhingran A, Levenback C, et al: Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 62:138, 2005
Frumovitz M, Etchepareborda M, Sun CC, et al: Primary malignant melanoma of the vagina. Obstet Gynecol 116:1358, 2010
Ghia AJ, Gonzalez VJ, Tward JD, et al: Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. Int J Gynecol Cancer 21:378, 2011
Gunderson CC, Nugent EK, Yunker AC, et al: Vaginal cancer: the experience from 2 large academic centers during a 15-year period. Journal of Lower Genital Tract Disease 17:409, 2013
Gupta D, Malpica A, Deavers MT, et al: Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 26:1450, 2002
Hamid O, Robert C, Ribas A, et al: Antitumor activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 119(6):670, 2018
Hanselaar A, van Loosbroek M, Schuurbiers O, et al: Clear cell adenocarcinoma of the vagina and cervix: an update of the central Netherlands registry showing twin age incidence peaks. Cancer 79:2229, 1997
Hays DM, Shimada H, Raney RB Jr, et al: Sarcomas of the vagina and uterus: the Intergroup Rhabdomyosarcoma Study. J Pediatr Surg 20:718, 1985
Hellman K, Lundell M, Silfversward C, et al: Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer 16:1201, 2006
Hilgers RD, Malkasian GD Jr, Soule EH: Embryonal rhabdomyosarcoma (botryoid type) of the vagina: a clinicopathologic review. Am J Obstet Gynecol 107:484, 1970
Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711, 2010
Hou JY, Baptiste C, Hombalegowda RB, et al: Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compares with 2253 cases of nongynecologic melanoma. Cancer 123(8):1333, 2017
Hu DN, Yu GP, McCormick SA: Population-based incidence of vulvar and vaginal melanoma in various races and ethnic groups with comparisons to other site-specific melanomas. Melanoma Res 20(2):153, 2010
Huh WK, Joura EA, Giuliano AR, et al: Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 390(10108):2143, 2017
Huo D, Anderson D, Palmer JR, et al: Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. Gynecol Oncol 146:566, 2017
Khafagy AM, Prescott LS, Mapica A, et al: Unusual indolent behavior of leiomyosarcoma of the vagina: Is observation a viable option? Gynecol Oncol Rep 21:28, 2017
Khosla D, Patel FD, Kumar R, et al: Leiomyosarcoma of the vagina: a rare entity with comprehensive review of the literature. Int J Appl Basic Med Res 4:128, 2014
Kunos CA, Radivoyevitch T, Waggoner S, et al: Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol 130:75, 2013
Lamoreaux WT, Grisby PW, Dehdashti F, et al: FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 62:733, 2005
Larkin J, Ascierto PA, Dreno B, et al: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867, 2014
Leitao MM: Management of vulvar and vaginal melanomas: current and future strategies. Am Soc Clin Oncol Educ Book 2014:e277, 2014
Long GV, Stroyakovskiy D, Gogas H, et al: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877, 2014
Long GV, Stroyakovskiy D, Gogas H, et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicenter, double-blind, phse 3 randomized controlled trial. Lancet 386:444, 2015
Melnick S, Cole P, Anderson D, et al: Rates and risks of diethylstilbestrolrelated clear-cell adenocarcinoma of the vagina and cervix: an update. N Engl J Med 316:514, 1987
Miner TJ, Delgado R, Zeisler J, et al: Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol 11:34, 2004
National Comprehensive Cancer Network: NCCN guidelines version 1.2019 Melanoma. Available at https://www.nccn.org/patients/guidelines/content/PDF/melanoma-patient.pdf. Accessed January 27, 2019
Nori D, Hilaris BS, Stanimir G, et al: Radiation therapy of primary vaginal carcinoma. Int J Radiat Oncol Biol Phys 9:1471, 1983
Pecorelli S, Benedet JL, Creasman WT, et al: FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 65:243, 1999
Perez CA, Grigsby PW, Garipagaoglu M, et al: Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys 44:37, 1999
Pingley S, Shrivastava SK, Sarin R, et al: Primary carcinoma of the vagina: Tata Memorial Hospital experience. Int J Radiat Oncol Biol Phys 46:101, 2000
Platz CE, Benda JA: Female genital tract cancer. Cancer 75:270, 1995
Ragnarsson-Olding B, Johansson H, Rutqvist LE, et al: Malignant melanoma of the vulva and vagina: trends in incidence, age distribution, and longterm survival among 245 consecutive cases in Sweden 1960–1984. Cancer 71:1893, 1993
Rajagopalan MS, Xu KM, Lin JF, et al: Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecol Oncol 135:495, 2014
Ratnavelu N, Patel A, Fisher AD, et al: High-grade vaginal intraepithelial neoplasia: can we be selective about who we treat? BJOG 120:887, 2013
Reddy S, Saxena VS, Reddy S, et al: Results of radiotherapeutic management of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys 21:1041, 1991
Reid GC, Schmidt RW, Roberts JA, et al: Primary melanoma of the vagina: a clinicopathologic analysis. Obstet Gynecol 74:190, 1989
Rubin SC, Young J, Mikuta JJ: Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up. Gynecol Oncol 20:346, 1985
Saitoh M, Hayasaka T, Ohmichi M, et al: Primary mucinous adenocarcinoma of the vagina: possibility of differentiating from metastatic adenocarcinomas. Pathol Int 55:372, 2005
Salani R, Khanna N, Frimer M, et al: An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146(1):3, 2017
Sandberg EC, Danielson RW, Cauwet RW, et al: Adenosis vaginae. Am J Obstet Gynecol 93:209, 1965
Senekjian EK, Frey KW, Anderson D, et al: Local therapy in stage I clear cell adenocarcinoma of the vagina. Cancer 60:1319, 1987
Senekjian EK, Frey KW, Stone C, et al: An evaluation of stage II vaginal clear cell adenocarcinoma according to substages. Gynecol Oncol 31:56, 1988
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69:7, 2019
Smith JS, Backes DM, Hoots BE, et al: Human papillomavirus type-distribution in vulvar and vaginal cancer and their associated precursors. Obstet Gynecol 113:917, 2009
Stock RG, Chen AS, Seski J: A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 56:45, 1995
Tewari KS, Sill MW, Long HJ, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734, 2014
Thigpen JT, Blessing JA, Homesley HD, et al: Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecol Oncol 23:101, 1986
Tran PT, Su Z, Lee P, et al: Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 105:641, 2007
Watson M, Saraiya M, Wu X: Update of HPV-associated female genital cancers in the United States, 1999–2004. J Womens Health 18:1731, 2009
Weinstock MA: Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 171:1225, 1994
Xia L, Han D, Yang W, et al: Primary malignant melanoma of the vagina. A retrospective clinicopathologic study of 44 cases. Int J Gynecol Cancer 24:149, 2014
Zaino RJ, Nucci M, Kurman RJ: Diseases of the vagina. In Kurman RJ, Ellenson LH, Ronnett BM (eds): Blaustein’s Pathology of the Female Genital Tract, 6th ed. New York, Springer, 2011, p 137
Zeligs KP, Byrd K, Tarney C, et al: A clinicopathologic study of vaginal intraepithelial neoplasia. Obstet Gynecol 122:1223, 2013
Balch CM, Gershenwald JE, Soong S, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199, 2009
Ballo MT, Garden AS, Myers JN, et al: Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck 27(8):718, 2005
Bell JG, Lea JS, Reid GC: Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. Gynecol Oncol 77:314, 2000
Binder SW, Huang I, Fu YS, et al: Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. Gynecol Oncol 37:9, 1990
Black D, Tornos C, Soslow RA, et al: The outcomes of patients with positive margins after excision for intraepithelial Paget’s disease of the vulva. Gynecol Oncol 104:547, 2007
Brinton LA, Nasca PC, Mallin K, et al: Case-control study of cancer of the vulva. Obstet Gynecol 75:859, 1990
Burke TW, Levenback C, Coleman RL, et al: Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 57:215, 1995
Casolati E, Agarossi A, Valieri M, et al: Vulvar neoplasia in HIV positive women: a review. Med Wieku Rozwoj 7(4 Pt 1):487, 2003
Chan JK, Sugiyama V, Pham H, et al: Margin distance and other clinicopathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 104:636, 2007
Cunningham MJ, Goyer RP, Gibbons SK, et al: Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 66:258, 1997
DiSaia PJ, Creasman WT (eds): Invasive cancer of the vulva. In Clinical Gynecologic Oncology, 5th ed. St. Louis, Mosby–Year Book, 1997, pp 202, 229
Donaldson ES, Powell DE, Hanson MB, et al: Prognostic parameters in invasive vulvar cancer. Gynecol Oncol 11:184, 1981
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522, 2015
Elit L, Voruganti S, Simunovic M: Invasive vulvar cancer in a woman with human immunodeficiency virus: case report and review of the literature. Gynecol Oncol 98:151, 2005
Eva LJ, Ganesan R, Chan KK, et al: Differentiated-type vulval intraepithelial neoplasia has a high-risk association with vulval squamous cell carcinoma. Int J Gynecol Cancer 19(4):741, 2009
Evans RA: Review and current perspectives of cutaneous malignant melanoma. J Am Coll Surg 179:764, 1994
Farias-Eisner R, Cirisano FD, Grouse D, et al: Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1–2N0–1M0) disease. Gynecol Oncol 53:55, 1994
Figge DC, Tamimi HK, Greer BE: Lymphatic spread in carcinoma of the vulva. Am J Obstet Gynecol 152:387, 1985
Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92:1500, 2000
Frumovitz M, Ramirez PT, Levenback C: Lymphatic mapping and sentinel node detection in gynecologic malignancies of the lower genital tract. Curr Oncol Rep 7(6):435, 2005
Gargano JW, Wilkinson EJ, Unger ER, et al: Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis 16(4):471, 2012
Garland SM, Joura EA, Ault KA, et al: Human papillomavirus genotypes from vaginal and vulvar intraepithelial neoplasia in females 15–26 years of age. Obstet Gynecol 132(2):261, 2018
Gordinier ME, Malpica A, Burke TW, et al: Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. Gynecol Oncol 90:625, 2003
Hacker NF, Berek JS, Lagasse LD, et al: Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol 63:155, 1984
Hacker NF, Berek JS, Lagasse LD, et al: Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol 61(4):408, 1983
Hallak S, Ladi L, Sorbe B: Prophylactic inguinal-femoral irradiation as an alternative to primary lymphadenectomy in treatment of vulvar carcinoma. Int J Oncol 31(5):1077, 2007
Halonen P, Jakobsson M, Heikinheimo O, et al: Lichen sclerosus and risk of cancer. Int J Cancer 140(9):1998, 2017
Heaps JM, Fu YS, Montz FJ, et al: Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 38(3):309, 1990
Homesley HD, Bundy BN, Sedlis A, et al: Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 164(4):997, 1991
Homesley HD, Bundy BN, Sedlis A, et al: Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). Gynecol Oncol 49(3):279, 1993
Homesley HD, Bundy BN, Sedlis A, et al: Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 68:733, 1986
Hoskins WJ, Perez CA, Young RC (eds): Vulva. In Principles and Practice of Gynecologic Oncology, 3rd ed. Philadelphia, Lippincott Williams & Wilkins, 2000, p 665
Huh WK, Joura EA, Giuliano AR, et al: Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 390(10108):2143, 2017
Irvin WP Jr, Legallo RL, Stoler MH, et al: Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 83:457, 2001
Jones RW, Rowan DM, Stewart AW: Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 106(6): 1319, 2005
Judson PL, Jonson AL, Paley PJ, et al: A prospective, randomized study analyzing Sartorius transposition following inguinal-femoral lymphadenectomy. Gynecol Oncol 95:226, 2004
Kirschner CV, Yordan EL, De Geest K, et al: Smoking, obesity, and survival in squamous cell carcinoma of the vulva. Gynecol Oncol 56:79, 1995
Kunos C, Simpkins F, Gibbons H, et al: Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 114:537, 2009
Kurman RJ, Carcangiu ML, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon, International Agency for Research on Cancer, 2014, p 231
Lens MB, Dawes M: Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20(7):1818, 2002a
Lens MB, Dawes M, Goodacre T, et al: Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg 137(10):1101, 2002b
Levenback C: Update on sentinel lymph node biopsy in gynecologic cancers. Gynecol Oncol 111(2 Suppl):S42, 2008
Levenback C, Morris M, Burke TW, et al: Groin dissection practices among gynecologic oncologists treating early vulvar cancer. Gynecol Oncol 62(1): 73, 1996
Madeleine MM, Daling JR, Carter JJ, et al: Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 89:1516, 1997
Magna N, Pacaut C, Auberdiac P, et al: Sarcoma of vulva, vagina and ovary. Best Pract Res Clin Obstet Gynaecol 25(6):797, 2011
Manavi M, Berger A, Kucera E, et al: Does T1, N0-1 vulvar cancer treated by vulvectomy but not lymphadenectomy need inguinofemoral radiation? Int J Radiat Oncol Biol Phys 38(4):749, 1997
McDermott DF, Shah R, Gupte-Singh K, et al: Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a qualityadjusted time without symptoms or toxicity (Q-TWiST) analysis. Qual Life Res 28(1):109, 2019
Modesitt SC, Waters AB, Walton L, et al: Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstet Gynecol 92(6):962, 1998
Moore D, Ali S, Barnes M, et al: A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. Gynecol Oncol 124(3):529, 2012
Moore DH, Thomas GM, Montana GS, et al: Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 42:79, 1998
Morley GW: Infiltrative carcinoma of the vulva: results of surgical treatment. Am J Obstet Gynecol 124:874, 1976
Moxley KM, Fader AN, Rose PG, et al: Malignant melanoma of the vulva: an extension of cutaneous melanoma? Gynecol Oncol 122(3):612, 2011
Nooij LS, van der Slot MA, Dekkers OM, et al: Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter? Eur J Cancer 65:139, 2016
Origoni M, Sideri M, Garsia S, et al: Prognostic value of pathological patterns of lymph node positivity in squamous cell carcinoma of the vulva stage III and IVA FIGO. Gynecol Oncol 45:313, 1992
Pang J, Assaad D, Breen D et al: Extramammary Paget disease: review of patients seen in a non-melanoma skin cancer clinic. Curr Oncol 17(5):43, 2010
Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105(2):103, 2009
Penn I: Cancers in renal transplant recipients. Adv Ren Replace Ther 7(2):147, 2000
Perez CA, Grigsby PW, Galakatos A, et al: Radiation therapy in management of carcinoma of the vulva with emphasis on conservation therapy. Cancer 71(11):3707, 1993
Petereit DG, Mehta MP, Buchler DA, et al: A retrospective review of nodal treatment for vulvar cancer. Am J Clin Oncol 16(1):38, 1993
Piura B, Egan M, Lopes A, et al: Malignant melanoma of the vulva: a clinicopathologic study of 18 cases. J Surg Oncol 50:234, 1992
Preti M, Rouzier R, Mariani L, et al: Superficially invasive carcinoma of the vulva: diagnosis and treatment. Clin Obstet Gynecol 48:862, 2005
Razzaghi H, Saraiya M, Thompson TD, et al: Five-year relative survival for human papillomavirus-associated cancer sites. Cancer 124(1):203, 2018
Reyes MC, Cooper K: An update on vulvar intraepithelial neoplasia: terminology and a practical approach to diagnosis. J Clin Pathol 67(4):290, 2014
Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517, 2011
Rouzier R, Haddad B, Dubernard G, et al: Inguinofemoral dissection for carcinoma of the vulva: effect of modifications of extent and technique on morbidity and survival. J Am Coll Surg 196:442, 2003
Salani R, Khanna N, Frimer M, et al: An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146(1):3, 2017
Salcedo MP, Sood AK, Dos Reis R, et al: Perineural invasion (PNI) in vulvar carcinoma: a review of 421 cases. Gynecol Oncol 152(1):101, 2019
Saraiya M, Unger ER, Thompson TD, et al: US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst 107(6):djv086, 2015
SEER: Surveillance, Epidemiology, and End Results Program: Cancer stat facts: vulvar cancer. 2018. Available at: https://seer.cancer.gov/statfacts/html/vulva.html Accessed March 28, 2019
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69(1):7, 2019
Stehman FB, Bundy BN, Thomas G, et al: Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 24(2):389, 1992
Stehman FB, Look KY: Carcinoma of the vulva. Obstet Gynecol 107(3):719, 2006
Tantipalakorn C, Robertson G, Marsden DE, et al: Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. Obstet Gynecol 113(4):895, 2009
Te Grootenhuis NC, van der Zee AG, van Doorn HC, et al: Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol 140(1):8, 2016
Van der Steen S, de Nieuwenhof HP, Massuger L, et al: New FIGO staging system of vulvar cancer indeed provides a better reflection of prognosis. Gynecol Oncol 119(3):520, 2010
Verschraegen CF, Benjapibal M, Supakarapongkul W, et al: Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. Int J Gynecol Cancer 11:359, 2001
Way S: The anatomy of the lymphatic drainage of the vulva and its influence on the radical operation for carcinoma. Ann R Coll Surg Engl 3(4):187, 1948
Wilkinson EJ: Premalignant and malignant tumors of the vulva. In Kurman RJ, Ellenson LH, Ronnett BM (eds): Blaustein’s Pathology of the Female Genital Tract, New York, Springer, 2011, p 95
Wilkinson EJ, Brown HM: Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease. Hum Pathol 33(5):549, 2002
Woelber L, Griebel LF, Eulenburg C, et al: Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gyn?kologische Onkologie CaRE-1 multicenter study. Eur J Cancer 69:180, 2016
Woolcott RJ, Henry RJ, Houghton CR: Malignant melanoma of the vulva: Australian experience. J Reprod Med 33:699, 1988
Abed Z, O’Leary M, Hand K, et al: Cervical screening history in patients with early stage carcinoma of the cervix. Ir Med J 99:140, 2006.
Abu-Rustum NR, Neubauer N, Sonoda Y, et al: Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol 111:261, 2008.
Abu-Rustum NR, Sonoda Y, Black D, et al: Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol 103:807, 2006.
Agorastos T, Chatzistamatiou K, Katsamagkas T, et al: Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS One 10:1, 2015.
Altgassen C, Hertel H, Brandstadt A, et al: Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO study group. J Clin Oncol 26:2943, 2008.
Baalbergen A, Smedts F, Helmerhorst TJ: Conservative therapy in microinvasive adenocarcinoma of the uterine cervix is justified. An analysis of 59 cases and a review of the literature. Int J Gynecol Cancer 21:1620, 2011.
Belhocine T, Thille A, Fridman V, et al: Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 87:90, 2002.
Benoit AG, Krepart GV, Lotocki RJ: Results of prior cytologic screening in patients with a diagnosis of stage I carcinoma of the cervix. Am J Obstet Gynecol 148:690, 1984.
Berek JS, Howe C, Lagasse LD, et al: Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 99:153, 2005.
Bhatla N, Berek JS, Cuello Fredes M, et al: Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129, 2019.
Bipat S, Glas AS, van der Velden J, et al: Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systemic review. Gynecol Oncol 91:59, 2003.
Bisseling KC, Bekkers RL, Rome RM, et al: Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature. Gynecol Oncol 107:424, 2007.
Bosch FX, Munoz N: The viral etiology of cervical cancer. Virus Res 89:183, 2002 Bouchard-Fortier G, Reade CJ, Covens A: Non-radical surgery for small earlystage cervical cancer. Is it time? Gynecol Oncol 132:624, 2014.
Brewer CA, Blessing JA, Nagourney RA, et al: Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 100(2):385, 2006.
Bulk S, Berkhof J, Bulkmans NW, et al: Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands. Br J Cancer 94:171, 2006.
Burnett AF, Roman LD, O’Meara AT, et al: Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol 88:419, 2003.
Cardonick E, Usmani A, Ghaffar S: Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy. Am J Clin Oncol 33:221, 2010.
Ceballos KM, Shaw D, Daya D: Microinvasive cervical adenocarcinoma (FIGO stage IA tumors), results of surgical staging and outcome analysis. Am J Surg Pathol 30:370, 2006.
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802, 2008.
Chung HC, Ros W, Delord JP, et al: Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol 37(17):1470, 2019.
Coleman RL, Keeney ED, Freedman RS, et al: Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 55:29, 1994.
Cosin JA, Fowler JM, Chen MD, et al: Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer 82:2241, 1998.
Covens A, Kirby J, Shaw P, et al: Prognostic factors for relapse and pelvic lymph node metastases in early stage I adenocarcinoma of the cervix. Gynecol Oncol 74:423, 1999a.
Covens A, Shaw P, Murphy J, et al: Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IA-B carcinoma of the cervix? Cancer 86:2273, 1999b.
Dargent D, Martin X, Saccetoni A, et al: Laparoscopic vaginal radical trachelectomy. Cancer 88:1877, 2000.
Datta GD, Colditz GA, Kawachi I, et al: Individual-, neighborhood-, and state-level socioeconomic predictors of cervical carcinoma screening among U.S. black women: a multilevel analysis. Cancer 106:664, 2006.
Delgado G, Bundy B, Zaino R, et al: Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38:352, 1990.
Downey GO, Potish RA, Adock LL, et al: Pretreatment surgical staging in cervical carcinoma: therapeutic efficacy of pelvic lymph node resection. Am J Obstet Gynecol 160:1055, 1989.
Dugue P, Rebolj M, Hallas J, et al: Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study. Int J Cancer 136:E711, 2015.
Eifel PJ, Burke TW, Delclos L, et al: Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. Gynecol Oncol 41:199, 1991.
Eifel PJ, Burke TW, Morris M, et al: Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59:38, 1995.
Eifel PJ, Morris M, Oswald MJ, et al: Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 65:2507, 1990.
Follen M, Levenback CF, Iyer RB, et al: Imaging in cervical cancer. Cancer 98(9S):2028, 2003 Gardner G, Reidy-Lagunes D, Gehrig PA: Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol 122(1):190, 2011.
Gien LT, Covens A: Fertility-sparing options for early stage cervical cancer. Gynecol Oncol 117:350, 2010.
Goff BA, Muntz HG, Paley PJ, et al: Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol 74:436, 1999.
Goldberg GL, Sukumvanich P, Einstein MH, et al: Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center experience (1987 to 2003). Gynecol Oncol 101:261, 2006.
Grigsby PW, Perez CA: Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ. Int J Radiat Oncol Biol Phys 21:375, 1991.
Grulich AE, van Leeuwen MT, Falster MO, et al: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59, 2007.
Guan P, Howell-Jones R, Li N, et al: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131:2349, 2012.
Hacker NF, Wain GV, Nicklin JL: Resection of bulky positive lymph nodes in patients with cervical carcinoma. Int J Gynecol Cancer 5:250, 1995.
Hamberger AD, Fletcher GH, Wharton JT: Results of treatment of early stage I carcinoma of the uterine cervix with intracavitary radium alone. Cancer 41:980, 1978.
Havrilesky LJ, Kulasingam SL, Matchar DB, et al: FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97: 183, 2005.
Helt AM, Funk JO, Galloway DA: Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol 76:10559, 2002.
Henriksen E: The lymphatic spread of carcinoma of the cervix and of the body of the uterus; a study of 420 necropsies. Am J Obstet Gynecol 58(5):924, 1949.
Holcomb K, Abulafia O, Matthews RP, et al: The impact of pretreatment staging laparotomy on survival in locally advanced cervical carcinoma. Eur J Gynaecol Oncol 20:90, 1999.
Hopkins MP, Schmidt RW, Roberts JA, et al: The prognosis and treatment of stage I adenocarcinoma of the cervix. Obstet Gynecol 72:915, 1988.
Hou J, Goldberg GL, Qualls CR, et al: Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis. Gynecol Oncol 121:135, 2011.
Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2016, National Cancer Institute. 2019.Available at: https://seer.cancer.gov/statfacts/html/cervix.html. Accessed July 2, 2019.
Hricak H, Gatsonis C, Chi, et al: Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651–Gynecologic Oncology Group 183. J Clin Oncol 23:9329, 2005.
Ijaz T, Eifel PJ, Burke T, et al: Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol 70:241, 1998.
International Collaboration of Epidemiological Studies of Cervical Cancer: Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 120:885, 2006.
International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599):1609, 2007.
Ito H, Shigematsu N, Kawada T, et al: Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol 67:154, 1997.
Jaworski RC, Roberts JM, Robboy SJ, et al: Cervical glandular neoplasia. In Robboy SJ, Mutter GL, Prat J, et al (eds): Robboy’s Pathology of the Female Reproductive Tract, 2nd ed. Churchill Livingstone Elsevier, 2009, p 273.
Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106, 2006 Jones DL, Munger K: Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71:2905, 1997.
Jones EE, Wells SI: Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways. Curr Mol Med 6:795, 2006.
Kadkhodayan S, Hasanzadeh M, Treglia G, et al: Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and metaanalysis of the pertinent literature. Eur J Surg Oncol 41:1, 2015.
Kapp KS, Poschauko J, Tauss J, et al: Analysis of the prognostic impact of tumor embolization before definitive radiotherapy for cervical carcinoma. Int J Radiat Oncol Biol Phys 62:1399, 2005.
Keighley E: Carcinoma of the cervix among prostitutes in a women’s prison. Br J Vener Dis 44:254, 1968.
Keys HM, Bundy BN, Stehman FB, et al: Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340: 1154, 1999.
Keys HM, Bundy BN, Stehman FB, et al: Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 89:343, 2003.
Koh WJ, Abu-Rustum NR, Bean S, et al: Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17(1):64, 2019.
Kolstad P: Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma). Gynecol Oncol 33:265, 1989.
Komaki R, Brickner TJ, Hanlon AL, et al: Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978, and 1983: Patterns of Care Study (PCS). Int J Radiat Oncol Biol Phys 31:973, 1995.
Koshiol J, Schroeder J, Jamieson DJ, et al: Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol 164:176, 2006.
Kupets R, Thomas GM, Covens A: Is there a role for pelvic lymph node debulking in advanced cervical cancer? Gynecol Oncol 87:163, 2002.
Lanciano R: Radiotherapy for the treatment of locally recurrent cervical cancer. J Natl Cancer Inst Monogr 21:113, 1996.
Landoni F, Maneo A, Colombo A, et al: Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350:535, 1997.
Landoni F, Maneo A, Cormio G, et al: Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. Gynecol Oncol 80:3, 2001.
Lea JS, Sheets EE, Wenham RM, et al: Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 84:115, 2002.
Leblanc E, Narducci F, Frumovitz, et al: Therapeutic value of pretherapeutic laparoscopic staging of locally advanced cervical carcinoma. Gynecol Oncol 105:304, 2007.
Leveque J, Laurent JF, Burtin F, et al: Prognostic factors of the uterine cervix adenocarcinoma. Eur J Obstet Gynecol Reprod Biol 80:209, 1998.
Ley C, Bauer HM, Reingold A, et al: Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 83:997, 1991.
Leyden WA, Manos MM, Geiger AM, et al: Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 97:675, 2005.
Long HJ III, Bundy BN, Grendys EC Jr, et al: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 23(21):4626, 2005.
Look KY, Brunetto VL, Clarke-Pearson DL, et al: An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 63:304, 1996.
Mantovani F, Banks L: Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene 18:3309, 1999.
McHale MT, Le TD, Burger RA, et al: Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol 98: 726, 2001.
Melamed A, Margul DJ, Chel L, et al: Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med 379:1905, 2018.
Million RR, Rutledge F, Fletcher GH: Stage IV carcinoma of the cervix with bladder invasion. Am J Obstet Gynecol 113:239, 1972.
Mitchell DG, Snyder B, Coakley F, et al: Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/ GOG 183 intergroup study. J Clin Oncol 24:5687, 2006.
Monk BJ, Sill MW, McMeekin DS, et al: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:1, 2009.
Moore DH, Blessing JA, McQuellon RP, et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22(15):3113, 2004.
Moreno V, Bosch FX, Mu?oz N, et al: Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359:1085, 2002.
Morris M, Blessing JA, Monk BJ, et al: Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22(16):3340, 2004.
Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137, 1999.
Morris M, Mitchell MF, Silva EG, et al: Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix. Gynecol Oncol 51:193, 1993.
Munger K, Basile JR, Duensing S, et al: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20:7888, 2001.
Munoz N, Franceschi S, Bosetti C, et al: Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359:1093, 2002.
Nakano T, Arai T, Morita S, et al: Radiation therapy alone for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 32:1331, 1995.
Olawaiye A, Del Carmen M, Tambouret R, et al: Abdominal radical trachelectomy: success and pitfalls in a general gynecologic oncology practice. Gynecol Oncol 112:506, 2009.
Ostor AG: Pandora’s box or Ariadne’s thread? Definition and prognostic significance of microinvasion in the uterine cervix. Squamous lesions. Pathol Annu 30(Pt 2):103, 1995.
Ostor AG, Rome RM: Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic study of 200 cases with long-term follow-up. Int J Gynecol Cancer 4:257, 1994.
Pareja R, Rendon GJ, Sanz-Lomana CM, et al: Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy: a systematic literature review. Gynecol Oncol 131:77, 2013.
Patsner B: Topical acetone for control of life-threatening vaginal hemorrhage from recurrent gynecologic cancer. Eur J Gynaecol Oncol 14:33, 1993.
Petereit DG, Hartenbach EM, Thomas GM: Para-aortic lymph node evaluation in cervical cancer: the impact of staging upon treatment decisions and outcome. Int J Gynecol Cancer 8:353, 1998.
Peters WA III, Liu PY, Barrett RJ, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606, 2000.
Piver MS, Rutledge F, Smith JP: Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44(2):265, 1974.
Plante M, Renaud MC, Hoskins IA, et al: Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol 98(1):3, 2005.
Plummer M, Herrero R, Franceschi S, et al: Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 14:805, 2003
Potter ME, Alvarez RD, Gay FL, et al: Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol 37:74, 1990.
Querleu D, Dargent D, Ansquer Y, et al: Extraperitoneal endosurgical aortic and common iliac dissection in the staging of bulky or advanced cervical carcinomas. Cancer 88:1883, 2000.
Quinn MA, Benedet JL, Odicino F, et al: Carcinoma of the cervix uteri. Int J Gynecol Obstet 95(suppl 1):S43, 2006.
Ramirez PT, Frumovitz M, Parja R, et al: Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 379:1895, 2018.
Ramirez PT, Soliman PT, Schmeler KM, et al: Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer. Gynecol Oncol 110:S21, 2008.
Reynolds EA, Tierney K, Keeney GL, et al: Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet Gynecol 116:1150, 2010.
Robinson WR, Webb S, Tirpack J, et al: Management of cervical intraepithelial neoplasia during pregnancy with LOOP excision. Gynecol Oncol 64:153, 1997.
Rose PG, Adler LP, Rodriguez M, et al: Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 17:41, 1999.
Salvo G, Ramirez PT, Leenback CF, et al: Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecol Oncol 145:96, 2017.
Schiffman MH, Bauer HM, Hoover RN, et al: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:958, 1993.
Schorge JO, Lee KR, Sheets EE: Prospective management of stage IA(1) cervical adenocarcinoma by conization alone to preserve fertility: a preliminary report. Gynecol Oncol 78:217, 2000.
Sedlis A, Bundy BN, Rotman MZ, et al: A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 73:177, 1999.
Selman TJ, Mann C, Zamora J, et al: Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ 178:855, 2008.
Shepherd JH, Milliken DA: Conservative surgery for carcinoma of the cervix. Clin Oncol 20:395, 2008.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69(1):7, 2019 Silver DF, Hempling RE, Piver MS, et al: Stage I adenocarcinoma of the cervix: does lesion size affect treatment options and prognosis? Am J Clin Oncol 21:431, 1998.
Sironi S, Buda A, Picchio M, et al: Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 238:272, 2006.
Smith HO, Qualls CR, Romero AA, et al: Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix? Gynecol Oncol 85:229, 2002.
Soost HJ, Lange HJ, Lehmacher W, et al: The validation of cervical cytology. Sensitivity, specificity and predictive values. Acta Cytol 35:8, 1991.
Spoozak L, Lewin S, Burke WM, et al: Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol 206:80, 2012.
Stehman FB, Bundy BN, DiSaia PJ, et al: Carcinoma of the cervix treated with radiation therapy. I. A multivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 67:2776, 1991.
Subak LL, Hricak H, Powell CB, et al: Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 86:43, 1995.
Sutton GP, Bundy BN, Delgado G, et al: Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol 166(1 Pt 1):50, 1992.
Tewari KS, Sill MW, Long HJ, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734, 2014.
Thigpen JT, Vance R, Puneky L, et al: Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 22(2 Suppl 3):16, 1995.
Tinga DJ, Timmer PR, Bouma J, et al: Prognostic significance of single versus multiple lymph node metastases in cervical carcinoma stage IB. Gynecol Oncol 39:175, 1990.
Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87, 2015 Trimble CL, Genkinger JM, Burke AE, et al: Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol 105:174, 2005.
Upadhyay SK, Symonds RP, Haelterman M, et al: The treatment of stage IV carcinoma of cervix by radical dose radiotherapy. Radiother Oncol 11:15, 1988.
Vale C, Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802, 2008.
Vasilev SA, McGonigle KF: Extraperitoneal laparoscopic paraaortic lymph node dissection: development of a technique. J Laparoendosc Surg 5:85, 1995.
Vercellino GF, Koehler C, Erdemoglu E, et al: Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer 24:364, 2014.
Vermorken JB: The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer 3:129, 1993.
Viswanathan AN, Deavers MT, Jhingran A, et al: Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 93:27, 2004.
Vizcaino AP, Moreno V, Bosch FX, et al: International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 86:429, 2000.
Walboomers JN, Jacons MV, Manos M, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12, 1999.
Webb MJ, Symmonds RE: Site of recurrence of cervical cancer after radical hysterectomy. Am J Obstet Gynecol 138(7 Pt 1):813, 1980.
Wei L, Griego AM, Chu M, et al: Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes. Carcinogenesis 35:2372, 2014.
Wentzensen N, Vinokurova S, von Knebel DM: Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64:3878, 2004.
Whitney CW, Sause W, Bundy BN, et al: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339, 1999.
World Health Organization: Cancer today: estimated number of new cases in 2018, worldwide, all cancers, female, all ages. 2019. Available at: https://gco.iarc.fr/today/home. Accessed July 1, 2019.
Wright JD, Dehdashti F, Herzog TJ, et al: Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-d-glucose-positron emission tomography. Cancer 104:2484, 2005.
Yahata T, Nishino K, Kashmima K, et al: Conservative treatment of stage IA1 adenocarcinoma of the uterine cervix with a long-term follow-up. Int J Gynecol Cancer 20:1063, 2010.
Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 1: overview, screening, and diagnosis. Oncology (Williston Park) 24(5):417, 2010.
Alemany L, Saunier M, Tinoco L, et al: Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 50(16):2846, 2014.
American Cancer Society: Key statistics for anal cancer. 2019a.
American Cancer Society: Key statistics for vaginal cancer. 2019b.
American Cancer Society: Key statistics for vulvar cancer. 2019c.
American College of Obstetricians and Gynecologists: Human papillomavirus vaccination. Committee Opinion No. 704, June, 2017.
American College of Obstetricians and Gynecologists: Cervical cancer screening and prevention. Practice Bulletin No. 168, October 2016, Reaffirmed 2018a.
American College of Obstetricians and Gynecologists: Management of abnormal cervical cancer screening results and cervical cancer precursors. Practice Bulletin No. 140, December, 2013. Reaffirmed 2018b.
American College of Obstetricians and Gynecologists: Management of vulvar intraepithelial neoplasia. Committee Opinion No. 675, October 2016, Reaffirmed 2019.
Barnes A, Betts AC, Borton EK, et al: Cervical cancer screening among HIVinfected women in an urban, United States safety-net healthcare system. AIDS 32(13):1861, 2018.
Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16, 2005.
Benard VB, Coughlin SS, Thompson T, et al: Cervical cancer incidence in the United States by area of residence, 1998–2001. Obstet Gynecol 110:681, 2007.
Benedet JL, Sanders BH: Carcinoma in situ of the vagina. Am J Obstet Gynecol 148(5):695, 1984.
Bergeron C, Ferenczy A, Richart RM, et al: Micropapillomatosis labialis appears unrelated to human papillomavirus. Obstet Gynecol 76(2):281, 1990.
Bigby SM, Eva LJ, Fong KL, et al: The natural history of vulvar intraepithelial neoplasia, differentiated type: evidence for progression and diagnostic challenges. Int J Gynecol Pathol 35(6):574, 2016.
Bogani G, Ditto A, Ferla S, et al: Treatment modalities for recurrent highgrade vaginal intraepithelial neoplasia. J Gynecol Oncol 30(2):e20, 2019.
Bornstein J, Bentley J, B?sze P, et al: 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 120(3):166, 2012.
Bornstein J, Bogliatto F, Haefner HK, et al: The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. Obstet Gynecol 127(2):264, 2016.
Bosch FX, Burchell AN, Schiffman M, et al: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 265:K1, 2008.
Brinton LA, Reeves WC, Brenes MM, et al: Parity as a risk factor for cervical cancer. Am J Epidemiol 130:486, 1989.
Brotherton JM, Budd A, Rompotis C, et al: Is one dose of human papillomavirus vaccine as effective as three? A national cohort analysis. Papillomavirus Res 8:100177, 2019.
Brown DR, Shew ML, Qadadri B, et al: A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191(2):182, 2005.
Bruni L, Diaz M, Castellsagu? X, et al: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789, 2010.
Buckley JD, Harris RW, Doll R, et al: Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. Lancet 2(8254):1010, 1981.
Burk RD, Ho GY, Beardsley L, et al: Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 174(4):679, 1996.
Case AS, Rocconi RP, Straughn JM Jr, et al: Cervical intraepithelial neoplasia in adolescent women. Obstet Gynecol 108:1369, 2006.
Castellsague X, Diaz M, de Sanjos? S, et al: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303, 2006.
Castle PE: Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 8(3):224, 2004.
Castle PE, Fetterman B, Poitras N, et al: Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 113:595, 2009a.
Castle PE, Fetterman B, Poitras N, et al: Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 115:243, 2010.
Castle PE, Hunt WC, Langsfeld E, et al: Three-year risk of cervical precancer and cancer after the detection of low-risk human papillomavirus genotypes targeted by a commercial test. Obstet Gynecol 123:49, 2014.
Castle PE, Kinney WK, Xue X, et al: Role of screening history in clinical meaning and optimal management of positive cervical screening results. J Natl Cancer Inst 111(8):820, 2019.
Castle PE, Schiffman M, Wheeler CM, et al: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 113:18, 2009b.
Castle PE, Stoler MH, Wright TC, et al: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12:880, 2011.
Castle PE, Walker JL, Schiffman M, et al: Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 117(6):1007, 2005.
Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines, 2010. MMWR 59(12): 1, 2010 Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines, 2015. MMWR 64(3):1, 2015.
Chang GJ, Berry JM, Jay N, et al: Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 45(4):453, 2002.
Chappell CA, West AM, Kabbani W, et al: Off-label high-risk HPV DNA testing of vaginal ASC-US and LSIL cytologic abnormalities at Parkland Hospital. J Low Genit Tract Dis 14(4):352, 2010.
Chaturvedi AK, Madeleine MM, Biggar RJ: et al: Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101(16):1120, 2009.
Chin-Hong PV, Reid GE, AST Infectious Diseases Community of Practice: Human papillomavirus infection in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33(9):e13590, 2019.
Cleveland AA, Gargano JW, Park IU, et al: Cervical adenocarcinoma in situ: human papillomavirus types and incidence trends in five states, 2008–2015. Int J Cancer April 13, 2019 [Epub ahead of print] Cohen BA, Honig P, Androphy E: Anogenital warts in children. Clinical and virologic evaluation for sexual abuse. Arch Dermatol 126(12):1575, 1990.
Collins S, Mazloomzadeh S, Winter H, et al: High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109(1):96, 2002.
Crum CP, Herrington CS, McCluggage WG, et al: Tumours of the vulva; epithelial tumors. In Kurman RJ, Carcangiu ML, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon, IARC Press, 2014.
Cuzick J, Clavel C, Petry KU, et al: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119:1095, 2006.
Darragh TM, Colga TJ, Cox JT, et al: The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 16(3):205, 2012.
Datta SD, Koutsky LA, Ratelle S, et al: Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003–2005. Ann Intern Med 148:493, 2008.
Del Pino M, Rodriguez-Carunchio L, Ordi J: Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology 62(1):161, 2013.
Demarco M, Lorey TS, Fetterman B, et al: Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of riskbased cervical screening guidelines. J Low Genit Tract Dis 21(4):261, 2017.
de Oliveira ER, Derchain SF, Sarian LO, et al: Prediction of high-grade cervical disease with human papillomavirus detect in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer 16:1055, 2006.
de Sanjose S, Palefsky J: Cervical and anal HPV infections in HIV positive women and men. Virus Res 89(2):201, 2002.
de Sanjose S, Serrano B, Tous S, et al: Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr 2(4):pky045, 2019.
de Vet HC, Sturmans F: Risk factors for cervical dysplasia: implications for prevention. Public Health 108(4):241, 1994.
de Villiers EM: Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 103(6):705, 2003.
De Vuyst H, Lillo F, Broutet N, et al: HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 17:545, 2008.
Diakomanolis E, Stefanidis K, Rodolakis A, et al: Vaginal intraepithelial neoplasia: report of 102 cases. Eur J Gynaecol Oncol 23(5):457, 2002.
Dick S, Kremer WW, De Strooper LM, et al: Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecol Oncol 154(2):368, 2019.
Dillner J: Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 25:11, 2013.
Dillner J: The serological response to papillomaviruses. Semin Cancer Biol 9(6):423, 1999.
Dodge JA, Eltabbakh GH, Mount SL, et al: Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol 83(2):363, 2001.
Doerfler D, Bernhaus A, Kottmel A, et al: Human papilloma virus infection prior to coitarche. Am J Obstet Gynecol 200:487.e1, 2009.
Doorbar J, Quint W, Banks L, et al: The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55, 2012.
Drolet M, B?nard ?, P?rez N, et al: Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 394(10197):497, 2019.
Dunne EF, Markowitz LE, Saraiya M, et al: CDC grand rounds: reducing the burden of HPV-associated cancer and disease. MMWR 63(4):69, 2014.
Dunne EF, Unger ER, Sternberg M, et al: Prevalence of HPV infection among females in the United States. JAMA 297:813, 2007.
Durst M, Kleinheinz A, Hotz M, et al: The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol 66(Pt 7):1515, 1985.
Economos K, Perez Veridiano N, Delke I, et al: Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol 81(6):915, 1993.
Ellerbrock TV, Chiasson MA, Bush TJ, et al: Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 283(8):1031, 2000.
Eva LJ, Ganesan R, Chan KK, et al: Vulval squamous cell carcinoma occurring on a background of differentiated vulval intraepithelial neoplasia is more likely to recur: a review of 154 cases. J Reprod Med 53:397, 2008.
Fairley CK, Chen S, Ugoni A, et al: Human papillomavirus infection and its relationship to recent and distant sexual partners. Obstet Gynecol 84(5):755, 1994.
Feng Q, Kiviat NB: New and surprising insights into pathogenesis of multicentric squamous cancers in the female lower genital tract. J Natl Cancer Inst 97: 1798, 2005.
Ferris DG, Cox JT, O’Connor DM: The biology and significance of human papillomavirus infection. In Haefner HK, Krumholz BA, Massad LS (eds): Modern Colposcopy. Dubuque, Kendall/Hunt Publishing Company, 2004, p 454.
Ferris DG, Litaker M: Interobserver agreement for colposcopy quality control using digitized colposcopic images during the ALTS trial. J Low Genit Tract Dis 9(1):29, 2005.
Fiascone S, Vitonis AF, Feldman S: Topical 5-fluorouracil for women with high-grade vaginal intraepithelial neoplasia. Obstet Gynecol 130(6):1237, 2017.
Food and Drug Administration: FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. 2018.
Food and Drug Administration: Gardasil approved to prevent anal cancer. 2010.
Franco EL, Villa LL, Ruiz A, et al: Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis 172(3):756, 1995.
Friedlander MA, Stier E, Lin O: Anorectal cytology as a screening tool for anal squamous lesions: cytologic, anoscopic, and histologic correlation. Cancer 102(1):19, 2004.
Friedrich EG Jr, Wilkinson EJ, Fu YS: Carcinoma in situ of the vulva: a continuing challenge. Am J Obstet Gynecol 136(7):830, 1980.
Frisch M, Glimelius B, van den Brule AJ, et al: Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337(19):1350, 1997.
Gage JC, Anson VW, Abbey K, et al: Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 108(2):264, 2006.
Goldstone SE, Kawalek AZ, Huyett JW: Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum 48(5):1042, 2005.
Goldstone SE, Winkler B, Ufford LJ, et al: High prevalence of anal squamous intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a surgical practice. Dis Colon Rectum 44(5):690, 2001.
Gomez-Lobo V: Gynecologic care of the transplant recipient. Postgrad Obstet Gynecol 29(10):1, 2009.
Griffith WF, Stuart GS, Gluck KL, et al: Vaginal speculum lubrication and its effects on cervical cytology and microbiology. Contraception 72:60, 2005.
Haefner HK, Tate JE, McLachlin CM, et al: Vulvar intraepithelial neoplasia: age, morphological phenotype, papillomavirus DNA, and coexisting invasive carcinoma. Hum Pathol 26(2):147, 1995.
Harmanli O, Jones KA: Using lubrication for speculum insertion. Obstet Gynecol 116(No. 2, Part 1):415, 2010.
Harris TG, Miller L, Kulasingam SL, et al: Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol 200:489.e1, 2009.
Hart WR: Vulvar intraepithelial neoplasia: historical aspects and current status. Int J Gynecol Pathol 20(1):16, 2001.
Heard I, Etienney I, Potard V, et al: High prevalence of anal human papillomavirus-associated cancer precursors in a contemporary cohort of asymptomatic HIV-infected women. Clin Infect Dis 60(10):1559, 2015.
Heard I, Palefsky JM, Kazatchkine MD: The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 9(1):13, 2004.
Heard I, Potard V, Foulot H, et al: High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr 39(4):412, 2005.
Hembree WC, Cohen-Kettenis PT, Gooren L, et al: Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 102(11):3869, 2017.
Henk HJ, Insigna RP, Singhal PK, et al: Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. Low Genit Tract Dis 4(1):29, 2010.
Herrero R, Hildesheim A, Bratti C, et al: Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92(6):464, 2000.
Herzog TJ, Monk BJ: Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol 197(6):566, 2007.
Hildesheim A, Hadjimichael O, Schwartz PE, et al: Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 180(3 Pt 1):571, 1999.
Hillemanns P, Ellerbrock TV, McPhillips S, et al: Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIVseropositive women. AIDS 10(14):1641, 1996.
Hirth JM, Kuo YF, Starkey JM, et al: Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014). Vaccine 37(30):4040, 2019.
Ho GY, Bierman R, Beardsley L, et al: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338(7):423, 1998.
Ho GY, Burk RD, Klein S, et al: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87(18):1365, 1995.
Hodeib M, Cohen JG, Mehta S, et al: Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN. Gynecol Oncol 141(3):507, 2016.
Hoffman MS, DeCesare SL, Roberts WS, et al: Upper vaginectomy for in situ and occult, superficially invasive carcinoma of the vagina. Am J Obstet Gynecol 166(1 Pt 1):30, 1992a.
Hoffman MS, Pinelli DM, Finan M, et al: Laser vaporization for vulvar intraepithelial neoplasia III. J Reprod Med 37(2):135, 1992b.
Holly EA, Ralston ML, Darragh TM, et al: Prevalence and risk factors for anal squamous intraepithelial neoplasia in women. J Natl Cancer Inst 93:843, 2001.
Hoover RN, Hyer M, Pfeiffer RM, et al: Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med 365 (14): 1304, 2011.
Hopkins MP, Nemunaitis-Keller J: Carcinoma of the vulva. Obstet Gynecol Clin North Am 28(4):791, 2001.
Howe HL, Wingo PA, Thun MJ, et al: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93(11):824, 2001.
Howlader N, Noone AM, Krapcho M, et al: SEER cancer statistics review, 1975–2014. Bethesda, National Cancer Institute, 2017.
Huh WK, Ault KA, Chelmow D, et al: Use of high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 125(2):330, 2015.
International Collaboration of Epidemiological Studies of Cervical Cancer: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609, 2007.
Jay N, Berry JM, Hogeboom CJ, et al: Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum 40(8):919, 1997.
Jeronimo J, Massad LS, Castle PE, et al: Interobserver agreement in the evaluation of digitized cervical images. Obstet Gynecol 110:833, 2007.
Jones RW, Rowan DM: Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol 84(5):741, 1994.
Jones RW, Rowan DM, Stewart AW: Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 106(6): 1319, 2005.
Joura EA, Zeisler H, Losch A, et al: Differentiating vulvar intraepithelial neoplasia from nonneoplastic epithelial disorders. The toluidine blue test. J Reprod Med 43(8):671, 1998.
Judson PL, Habermann EB, Baxter NN, et al: Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018, 2006.
Kaplan JE, Benson C, Holmes KH, et al: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR 58(4):1, 2009 Khan MJ, Castle PE, Lorincz AT, et al: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97:1072, 2005.
Khan MJ, Massad LS, Kinney W, et al: A common clinical dilemma: management of abnormal vaginal cytology and human papillomavirus test results. J Low Genit Tract Dis 20(2):119, 2016.
Khan MJ, Smith-McCune KK: Treatment of cervical precancers: back to basics. Obstet Gynecol 123(6):1339, 2014.
Khan MJ, Werner CL, Darragh TM, et al: ASCCP colposcopy standards: role of colposcopy, benefits, potential harms, and terminology for colposcopic practice. J Low Genit Tract Dis 21(4):223, 2017.
Kinney WK, Manos MM, Hurley LB, et al: Where’s the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 91(6):973, 1998.
Kiviat N: Natural history of cervical neoplasia: overview and update. Am J Obstet Gynecol 175(4 Pt 2):1099, 1996.
Kjaer SK, de Villiers EM, Dahl C, et al: Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the “male factor” in women with one lifetime sexual partner. Int J Cancer 48(1):39, 1991.
Kjaer SK, van den Brule AJ, Paull G, et al: Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325(7364):572, 2002.
Korn AP, Abercrombie PD, Foster A: Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus-1. Gynecol Oncol 61:384, 1996.
Kosary C: Cancer of the vagina. In Ries LAG, Young JL, Keel GE, et al (eds): SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. NIH Publication No. 07–6215, Bethesda, 2007.
Koss LG: The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 261(5):737, 1989.
Krebs HB: Treatment of vaginal intraepithelial neoplasia with laser and tropical 5-fluorouracil. Obstet Gynecol 73(4):657, 1989.
Kreimer AR, Herrero R, Sampson JN, et al: Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine 36(32 Pt A):4774, 2018.
Krivak TC, Rose GS, McBroom JW, et al: Cervical adenocarcinoma in situ: a systematic review of therapeutic options and predictors of persistent or recurrent disease. Obstet Gynecol Surv 56(9):567, 2001.
Lamme J, Pattaratornkosohn T, Mercado-Abadie J, et al: Concurrent anal human papillomavirus and abnormal anal cytology in women with known cervical dysplasia. Obstet Gynecol 124(2Pt 1), 242, 2014.
Lawrie TA, Nordin A, Chakrabarti M, et al: Medical and surgical interventions for the treatment of usual?type vulval intraepithelial neoplasia. Cochrane Database Syst Rev 1:CD011837, 2016.
Le T, Menard C, Hicks-Boucher W, et al: Final results of a phase 2 study using continuous 5% imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol 106(3):579, 2007.
Lee A, Radford J, Fischer G: Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol 151:1061, 2015.
Lin C, Slama J, Gonzalez P, et al: Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infect Dis 19(8):880, 2019.
Mahto M, Nathan M, O’Maony C: More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Int J STD AIDS 21:8, 2010.
Maiman M, Fruchter RG, Serur E, et al: Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 38:377, 1990.
Markowitz LE, Naleway AL, Lewis RM, et al: Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination. Vaccine 37(29):3918, 2019.
Marrazzo JM, Stine K, Koutsky LA: Genital human papillomavirus infection in women who have sex with women: a review. Am J Obstet Gynecol 183(3):770, 2000.
Martin-Hirsch PL, Paraskevaidis E, Bryant A: Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 6:CD001318, 2013.
Massad LS, Einstein MH, Huh WK, et al: 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 17(5):S1, 2013.
Massad LS, Seaberg EC, Watts DH, et al: Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer 115:524, 2009.
Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNS versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357(16):1579, 2007.
McClung NM, Gargano JW, Park IU, et al: Estimated number of cases of high-grade cervical lesions diagnosed among women—United States, 2008 and 2016. MMWR 68(15):337, 2019.
McCredie MRE, Sharples KJ, Paul C, et al: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9(5):425, 2008.
McCune KC, Imborek KL: Clinical care of lesbian and bisexual women for the obstetrician gynecologist. Clin Obstet Gynecol 61(4):663, 2018.
Meites E, Kempe A, Markowitz LE: Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. MMWR 65(49):1405, 2016.
Meites E, Szilagyi PG, Chesson HW, et al: Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR 68:698, 2019.
Miller BE: Vulvar intraepithelial neoplasia treated with cavitational ultrasonic surgical aspiration. Gynecol Oncol 85(1):114, 2002.
Molijn A, Kleter B, Quint W, et al: Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 32(Suppl 1):S43, 2005.
Moore K, Cofer A, Elliot L, et al: Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 197:141.e1, 2007.
Moscicki AB: Impact of HPV infection in adolescent populations. J Adolesc Health 37:S3, 2005.
Moscicki AB, Darragh TM, Berry-Lawhorn JM, et al: Screening for anal cancer in women. J Low Genit Tract Dis 19(301):S26, 2015.
Moscicki AB, Flowers L, Huchko MJ, et al: Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis 23(2):87, 2019.
Moscicki AB, Ma Y, Wibbelsman C, et al: Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 116(6):1373, 2010.
Moscicki AB, Shiboski S, Broering J, et al: The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 132(2):277, 1998.
Moscicki AB, Shiboski S, Hills NK, et al: Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364(9446):1678, 2004.
Munoz N, Bosch FX, de Sanjose S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518, 2003.
Munoz N, Franceschi S, Bosetti C, et al: Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359:1093, 2002.
Nahas CS, da Silva Filho EV, Segurado AA, et al: Screening anal dysplasia in HIV-infected patients: is there an agreement between anal Pap smear and high-resolution anoscopy-guided biopsy? Dis Colon Rectum 52:1854, 2009.
National Cancer Institute: PDQ Cervical Cancer Screening. 2019a.
National Cancer Institute: Vulvar cancer treatment PDQ®. 2019b.
Nayar R, Wilbur DC: The Pap test and Bethesda 2014. Cancer Cytopathol 123(5):271, 2015.
Obalek S, Jablonska S, Favre M, et al: Condylomata acuminata in children: frequent association with human papillomaviruses responsible for cutaneous warts. J Am Acad Dermatol 23(2 Pt 1):205, 1990.
Ostor AG: Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12(2):186, 1993.
Palefsky JM: Anal human papillomavirus infection and anal cancer in HIVpositive individuals: an emerging problem. AIDS 8:283, 1994.
Palefsky JM, Holly EA, Efirdc JT, et al: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19(13):1407, 2005.
Palefsky JM, Holly EA, Ralston ML, et al: Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)- positive and high-risk HIV-negative women. J Infect Dis 183(3):383, 2001.
Panel on Opportunistic Infections in Adults and Adolescents with HIV: Guidelines for the prevention and treatment of opportunistic infections in Adults and Adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2019. Panther LA, Schlecht HP, Dezube BJ: Spectrum of human papillomavirusrelated dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read 15(2):79, 2005.
Paraskevaidis E, Jandial L, Mann E, et al: Pattern of treatment failure following laser for cervical intraepithelial neoplasia: implications for follow-up protocol. Obstet Gynecol 78:80, 1991.
Perrotta M, Marchitelli CE, Velazco AF, et al: Use of CO2 laser vaporization for the treatment of high-grade vaginal intraepithelial neoplasia. J Low Genit Tract Dis 17(1):23, 2013.
Petrosky E, Bocchini JA Jr, Hariri S, et al: Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR 64(11):300, 2015.
Plummer M, Herrero R, Franceschi S, et al: Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 14(9):805, 2003.
Punnonen R, Kallioniemi OP, Mattila J, et al: Primary invasive and in situ vaginal carcinoma. Flow cytometric analysis of DNA aneuploidy and cell proliferation from archival paraffin-embedded tissue. Eur J Obstet Gynecol Reprod Biol 32(3):247, 1989.
Remmink AJ, Walboomers JM, Helmerhorst TJ, et al: The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 61(3):306, 1995.
Rome RM, England PG: Management of vaginal intraepithelial neoplasia: a series of 132 cases with long-term follow-up. Int J Gynecol Cancer 10:382, 2000.
Ronco G, Dillner J, Elfstr?m KM, et al: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383(9916):524, 2014.
Ronco G, Giorgi-Rossi P, Carozzi F, et al: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. Lancet Oncol 11:249, 2010.
Ronco G, Segnan N, Giorgi-Rossi P, et al: Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98(11):765, 2006.
Rosales R, Rosales C: Immune therapy for human papillomavirus-related cancers. World J Clin Oncol 5(5):1002, 2014.
Rosenfeld WD, Rose E, Vermund SH, et al: Follow-up evaluation of cervicovaginal human papillomavirus infection in adolescents. J Pediatr 121(2):307, 1992.
Roura E, Travier N, Waterboer T, et al: The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One 11(1):e0147029, 2016.
Santoso J, Long M, Crigger M, et al: Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol 116(3):578, 2010.
Sapp M, Bienkowska-Haba M: Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J 276:7206, 2009.
Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer 62(3):147, 2012.
Schiffman M, Kinney WK, Cheung LC, et al: Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst 110(5):501, 2018.
Schiffman M, Wentzensen N: From human papillomavirus to cervical cancer. Obstet Gynecol 116(1):177, 2010.
Schlecht NF, Platt RW, Duarte-Franco E, et al: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95(17):1336, 2003.
Schnatz PF, Guile M, O’Sullivan DM, et al: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 107:701, 2006.
Schockaert S, Poppe W, Arbyn M, et al: Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. Am J Obstet Gynecol 199:113.e1, 2008.
Sehnal B, Dusek L, Cibula D, et al: The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. J Clin Virol 59(1):18, 2014.
Shatz P, Bergeron C, Wilkinson EJ, et al: Vulvar intraepithelial neoplasia and skin appendage involvement. Obstet Gynecol 74(5):769, 1989.
Sherman ME, Friedman HB, Busseniers AE, et al: Cytologic diagnosis of anal intraepithelial neoplasia using smears and cytyc thin-preps. Mod Pathol 8(3):270, 1995.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69:7, 2019.
Silverberg MJ, Thorsen P, Lindeberg H, et al: Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 101(4):645, 2003.
Smith JS, Backes DM, Hoots BE, et al: Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 113(4):917, 2009.
Smith JS, Lindsay L, Hoots B, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621, 2007.
Solomon D, Davey D, Kurman R, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287(16):2114, 2002.
Spitzer M: Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv 54(2):131, 1999.
Spitzer M, Krumholz BA, Seltzer VL: The multicentric nature of disease related to human papillomavirus infection of the female lower genital tract. Obstet Gynecol 73(3 Pt 1):303, 1989.
Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117:S5, 2010a.
Stanley M: Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 23:70, 2010b.
Stoler MH: A brief synopsis of the role of human papillomaviruses in cervical carcinogenesis. Am J Obstet Gynecol 175(4 Pt 2):1091, 1996.
Strander B, H?llgren J, Spar?n P: Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia 3: population based cohort study of long term incidence and mortality. BMJ 348:17361, 2014.
Syrjonen S: Current concepts on human papillomavirus infections in children. APMIS 118(6-7):494, 2010.
Tandon R, Baranoski AS, Huang F, et al: Abnormal anal cytology in HIVinfected women. Am J Obstet Gynecol 203:21.e1, 2010.
Thimm MA, Rositch AF, VandenBussche C, et al: Lower genital tract dysplasia in female solid organ transplant recipients. Obstet Gynecol 134(2):385, 2019.
Thomsen LT, Frederiksen K, Munk C, et al: High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancer. Obstet Gynecol 123:57, 2014.
Trimble EL: A guest editorial: update on diethylstilbestrol. Obstet Gynecol Surv 56(4):187, 2001.
Trottier H, Mahmud SM, Lindsay L, et al: Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev 18(3):854, 2009.
U.S. Preventive Services Task Force, Curry SJ, Krist AH, et al: Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 320(7):674, 2018.
Ulfelder H, Robboy SJ: The embryologic development of the human vagina. Am J Obstet Gynecol 126(7):769, 1976.
van de Nieuwenhof HP, Massuger LF, van der Avoort I, et al: Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer 45(5):851, 2009.
van den Einden LC, de Hullu JA, Massuger LF, et al: Interobserver variability and the effect of education in the histopathological diagnosis of differentiated vulvar intraepithelial neoplasia. Mod Pathol 26:874, 2013.
van Seters M, van Beurden M, ten Kate FJ, et al: Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 358:1465, 2008.
Verdoodt F, Jiang X, Williams M, et al: High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis. Int J Cancer 138(2):303, 2016.
Verloop J, van Leeuwen FE, Helmerhorst TJ, et al: Risk of cervical intraepithelial neoplasia and invasive cancer of the cervix in DES daughters. Gynecol Oncol 144(2):305, 2017.
von Gruenigen VE, Gibbons HE, Gibbins K, et al: Surgical treatments for vulvar and vaginal dysplasia. Obstet Gynecol 109:942, 2007.
Walker TY, Elam-Evans LD, Yankey D, et al: National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2018. MMWR 68(33):718, 2019.
Wang CJ, Sparano J, Palefsky J: HIV/AIDS, HPV and anal cancer. Surg Oncol Clin N Am 26(1):17, 2017 Watson AJ, Smith BB, Whitehead MR, et al: Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg 76(8):715, 2006.
Wentzensen N, Clarke MA, Bremer R, et al: Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Intern Med 179(7):881, 2019.
Wentzensen N, Massad LS, Mayeaux EJ Jr, et al: Evidence-based consensus recommendations for colposcopy practice for cervical cancer prevention in the United States. J Low Genit Tract Dis 21(4):216, 2017.
Whitlock EP, Vesco KK, Eder M, et al: Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 155:687, 2011.
Wilkinson EJ: Pap smears and screening for cervical neoplasia. Clin Obstet Gynecol 33(4):817, 1990.
Wilkinson EJ, Kneale B, Lynch PJ: Report of the ISSVD Terminology Committee. J Reprod Med 31:973, 1986.
Winer RL, Hughes JP, Feng Q, et al: Early natural history of incident, typespecific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20(4):699, 2011.
Winer RL, Lee SK, Hughes JP, et al: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157(3):218, 2003.
Woodman CB, Collins S, Winter H, et al: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357(9271):1831, 200.
Woodruff JD: Carcinoma in situ of the vagina. Clin Obstet Gynecol 24(2):485, 1981.
Wright TC, Ellerbrock TV, Chiasson MA, et al: Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 84(4):591, 1994.
Wright TC, Stoler MH, Behrens CM, et al: Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 136(2):189, 2015.
Wright TC, Stoler MH, Behrens CM, et al: The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 206:46e1, 2012.
Wright VC, Chapman W: Intraepithelial neoplasia of the lower female genital tract: etiology, investigation, and management. Semin Surg Oncol 8:180, 1992.
Yasmeen S, Romano PS, Pettinger M, et al: Incidence of cervical cytological abnormalities with aging in the Women’s Health Initiative. Obstet Gynecol 108:410, 2006.
Yeh PT, Kennedy CE, de Vuyst H, et al: Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob Health 4(3):e001351, 2019.
Yost NP, Santoso JT, McIntire DD, et al: Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol 93(3):359, 1999.
Zbar AP, Fenger C, Efron J, et al: The pathology and molecular biology of anal intraepithelial neoplasia: comparisons with cervical and vulvar intraepithelial carcinoma. Int J Colorectal Dis 17(4):203, 2002.
zur Hausen H: Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384(2):260, 2009.
Adli M, Mayr NA, Kaiser HS et al: Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer? Int J Radiat Oncol Biol Phys 57(1):230, 2003
American College of Radiology: Appropriateness criteria. 2018.
Amorino GP, Freeman ML, Carbone DP, et al: Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys 44(2):399, 1999
Arai T, Nakano T, Fukuhisa K, et al: Second cancer after radiation therapy for cancer of the uterine cervix. Cancer 67(2):398, 1991
Arriva L, Chang YC, Hricak H, et al: Radiation-induced uterine changes: MR imaging. Radiology 170(1 Pt 1):55, 1989 Ash P: The influence of radiation on fertility in man. Br J Radiol 53:271, 1980
ASTEC/EN.5 Study Group: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review and meta-analysis. Lancet 373:137, 2009
Begg AC: Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19(5):1183, 1990
Bentzen SM: Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 36(1):247, 1996
Beriwal S, Demanes DJ, Erickson B, et al: American Brachytherapy Society consensus guideline for interstitial brachytherapy for vaginal cancer. Brachytherapy 11(1):68, 2012
Boronow RC: Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer: rationale and results. Cancer 49(6):1085, 1982
Brizel DM, Dodge RK, Clough RW, et al: Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53(2):113, 1999
Cooper KL, Beabout JW, Swee RG: Insufficiency fractures of the sacrum. Radiology 156:15, 1985
Creutzberg CL, Nout RA, Lybeert ML, et al: Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81(4):631, 2011
Critchley HO, Wallace WH, Shalet SM, et al: Abdominal irradiation in childhood: the potential for pregnancy. BJOG 99(5):392, 1992
Dische S, Saunders MI, Sealy R, et al: Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiother Oncol 53(2):93, 1999
DiSilvestro PA, Ali S, Craighead PS, et al: Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol 32(5):458, 2014
Dubben HH: Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 47(2):167, 1998
Duesas-Gonzalez A, Zarb? JJ, Patel F, et al: Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 29(13):1678, 2011
Dunst J, Kuhnt T, Strauss HG, et al: Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56(3):778, 2003
Fajardo LF: The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 44(1):13, 2005
Friedlander AH, Freymiller EG: Detection of radiation-accelerated atherosclerosis of the carotid artery by panoramic radiography. A new opportunity for dentists. J Am Dent Assoc 134(10):1361, 2003
Frumovitz M, Sun CC, Schover LR, et al: Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428, 2005
Gemignani ML, Alektiar KM, Leitai M, et al: Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys 50(3):687, 2001
Gondi V, Bentzen SM, Sklenar KL et al: Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. Int J Radiat Oncol Biol Phys 84(4):973, 2012
Grigsby P, Winter K, Komaki R et al: Long-term follow-up of RTOG 88-05: twice-daily external irradiation with brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54:51, 2002
Grigsby PW, Heydon K, Mutch DG et al: Long-term follow up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 51(4):982, 2001
Hareyama M, Sakata K, Oouchi A, et al: High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 94(1):117, 2002
Heron DE, Gerszten K, Selvaraj RN, et al: Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms. Gynecol Oncol 91(1):39, 2003
Herrera FG, Cruz OS, Achtari C, et al: Long-term outcome and late side effects in endometrial cancer patients treated with surgery and postoperative radiation therapy. Ann Surg Oncol 21(7):2390, 2014
Hoffman JP, Sigurdson ER, Eisenberg BL: Use of saline-filled tissue expanders to protect the small bowel from radiation. Oncology 12(1):51, 1998
Irtan S, Orbach D, Helfre S, et al: Ovarian transposition in prepubescent and adolescent girls with cancer. Lancet Oncol 14:e601, 2013
Janssens GO, Rademakers SE, Terhaard CH, et al: Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. Clin Cancer Res 20(5):1345, 2014
Jensen PT, Groenvold M, Klee MC, et al: Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 56(4):937, 2003
Jones E, Beriwal S, Beyer D, et al: An analysis of appropriate postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: Executive Summary. Advances Radiat Oncol 1(1): 26, 2016
Kantsevoy SV, Cruz-Correa MR, Vaughn CA, et al: Endoscopic cryotherapy for the treatment of bleeding mucosal vascular lesions of the GI tract: a pilot study. Gastrointest Endosc 57(3):403, 2003
Kapp KS, Poschauko J, Geyer E, et al: Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 54(1):58, 2002
Keys HM, Bundy BN, Stehman FB, et al: A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. N Engl J Med 340:1154, 1999
Keys HM, Bundy BN, Stehman FB et al: Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 89(3):343, 2003
Keys HM, Roberts JA, Brunetto VL, et al: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744, 2004
Klopp AH, Moughan J, Portelance L, et al: Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancers. Int J Radiat Oncol Biol Phys 86(1):83, 2013
Klopp AH, Smith BD, Alektiar K, et al: The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation Oncology evidence-based guideline. Prac Radiat Oncol 4(1):137, 2014
Konishi T, Watanabe T, Kitayama J, et al: Endoscopic and histopathologic findings after formalin application for hemorrhage caused by chronic radiation-induced proctitis. Gastrointest Endosc 61(1):161, 2005
Lee LJ, Das IJ, Higgins SA, et al: American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-doserate and pulsed-dose-rate brachytherapy. Brachytherapy 11(1):53, 2012a
Lee LJ, Viswanathan AN: Predictors of toxicity after image-guided high-doserate interstitial brachytherapy for gynecologic cancer. Int J Radiat Oncol Biol Phys 84(5):1192, 2012b
Lee MY, Wu HG, Kim K, et al: Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecol Oncol 104(1):95, 2007
Mark RJ, Poen J, Tran LM et al: Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am J Clin Oncol 19(1):59, 1996
Martin J, Fitzpatrick K, Horan G, et al: Treatment with a belly-board device significantly reduces the volume of small bowel irradiated and results in low acute toxicity in adjuvant radiotherapy for gynecologic cancer: results of a prospective study. Radiother Oncol 74(3):267, 2005
Mason KA, Kishi K, Hunter N, et al: Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 5:4191, 1999
Milano MT, Constine LS, Okunieff P: Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 17:131, 2007
Montana GS, Thomas GM, Moore DH, et al: Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 48(4):1007, 2000
Morris M, Eifel PJ, Watkins EB, et al: Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high risk cervical cancer: a randomized Radiation Therapy Oncology Group clinical trial. N Engl J Med 340:1137, 1999
National Cancer Institute: Common terminology criteria for adverse events v5.0. NCI, NIH, DHHS. November 27, 2017.
Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41(1):31, 1996
Nout RA, Smit VT, Putter H, et al: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816, 2010
Oh D, Huh SJ, Nam H et al: Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors. Int J Radiat Oncol Biol Phys 70(4):1183, 2008
Okada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4(8):592, 2004
Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59(4):928, 2004
Petereit DG, Sarkaria JN, Chappell R, et al: The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 32(5): 1301, 1995
Peters WA, Liu PY, Barrett RJ, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18(8):1606, 2000
Portelance L, Chao KS, Grigsby PW, et al: Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 51(1):261, 2001
Potter R, Haie-Meder C, Van Limbergen E, et al: Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67, 2006
Reulen RC, Zeegers MP, Wallace WH, et al: Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 18(8):2239, 2009
Rose PG, Bundy BN, Watkins EB, et al: Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. N Engl J Med 340:1144, 1999
Schwartz JL, Mustafi R, Beckett MA, et al: DNA double-strand break rejoining rates, inherent radiation sensitivity and human tumor response to radiotherapy. Br J Cancer 74(1):37, 1996
Schwartz JL, Rotmensch J, Giovanazzi S, et al: Faster repair of DNA doublestrand breaks in radioresistant human tumor cells. Int J Radiat Oncol Biol Phys 15(4):907, 1988
Sedlis A, Bundy BN, Rotman MZ, et al: A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol 73(2)177, 1999
Sepponen VI, Artama MS, Malila NK, et al: Risk for congenital anomalies in offspring of childhood, adolescent and young adult cancer survivors. Int J Cancer 139:1721, 2016
Shih KK, Folkert MR, Kollmeier MA, et al: Pelvic insufficiency fractures in patients with cervical and endometrial cancer treated with postoperative pelvic radiation. Gynecol Oncol 128(3):540, 2013
Signorello LB, Mulvihill JJ, Green DM, et al: Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol 30(3):239, 2012
Signorello LB, Mulvihill JJ, Green DM, et al: Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet 376:624, 2010
Small W, Beriwal S, Demanes DJ, et al: American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 11(1):58, 2012
Small W, Winter K, Levenback C et al: Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of RTOG 0116. Int J Gynecol Cancer 21(7):1266, 2011
Smith S, Wallner K, Dominitz JA, et al: Argon plasma coagulation for rectal bleeding after prostate brachytherapy. Int J Radiat Oncol Biol Phys 51(3):636, 2001
Soper JT, Clarke-Pearson DL, Creasman WT: Absorbable synthetic mesh (910-polyglactin) intestinal sling to reduce radiation-induced small bowel injury in patients with pelvic malignancies. Gynecol Oncol 29(3):283, 1988
Stanic S, Mayadev JS: Tolerance of the small bowel to therapeutic irradiation: a focus on late toxicity in patients receiving para-aortic nodal irradiation for gynecologic malignancies. Int J Gynecol Cancer 23(4):592, 2013
Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapychemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5(1):85, 1979
Thomas G, Ali S, Hoebers FJ, et al: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108(2):317, 2008
Trott KR: The mechanisms of acceleration of repopulation in squamous epithelia during daily irradiation. Acta Oncol 38(2):153, 1999
Ventrucci M, Di Simone MP, Giulietti P, et al: Efficacy and safety of Nd:YAG laser for the treatment of bleeding from radiation proctocolitis. Dig Liver Dis 33(3):230, 2001
Verma J, Sulman EP, Jhingran A et al: Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys 88(2):357, 2014
Viswanathan AN, Beriwal S, De Los Santos JF, et al: American Brachytherapy Society consensus guideline for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 11(1):47, 2012a
Viswanathan AN, Thomadsen B: American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11(1):33, 2012b
Weichselbaum RR, Beckett MA, Hallahan DE, et al: Molecular targets to overcome radioresistance. Semin Oncol 19(4 Suppl 11):14, 1992
Winther JF, Boice JD Jr, Svendsen AL, et al: Spontaneous abortion in a Danish population-based cohort of childhood cancer survivors. J Clin Oncol 26:4340, 2008
Winther JF, Olsen JH, Wu H, et al: Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol 30:27, 2012
Wong FC, Tung SY, Leung TW, et al: Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens. Int J Radiat Oncol Biol Phys 55(5):1254, 2003
Zidar N, Ferlunga D, Hvala A, et al: Contribution to the pathogenesis of radiation-induced injury to large arteries. J Laryngol Otol 111(10):988, 1997
Aapro M, Jelkmann W, Constantinescu SN, et al: Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 106(7):1249, 2012
Alazzam M, Tidy J, Osborne R, et al: Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 1:CD008891, 2016
Alvarez EA, Brady WE, Walker JL, et al: Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 129(1):22, 2013
Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34, 2006
Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98(10):708, 2006
Bower M, Newlands ES, Holden L, et al: EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 15(7):2636, 1997
Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473, 2011
Burger RA, Brady MF, Bookman MA, et al: Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 32(12):1210, 2014
Burstein HJ, Mangu PB, Somerfield MR, et al: American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29(24):3328, 2011
Cannistra SA, Matulonis UA, Penson RT, et al: Phase III study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180, 2007
Cantu MG, Buda A, Parma G, et al: Randomized controlled trial of singleagent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinumbased regimens. J Clin Oncol 20(5):1232, 2002
Case AS, Rocconi RP, Kilgore LC, et al: Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Gynecol Oncol 101(3):499, 2006
Chen H, Li J, Cui T, et al: Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 11:CD008018, 2011
Chung HC, Schellens JH, Delord JP, et al: Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. J Clin Oncol 36(15 suppl):5522, 2018
Chura JC, Van Iseghem K, Downs LS Jr, et al: Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107(2):326, 2007
Coleman RL, Oza AM, Lorusso D, et al: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10106):1949, 2017
Dizon DS, Sill MW, Gould N, et al: Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 123(2):182, 2011
Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228, 2009
Elgindy EA, El-Haieg DO, Khorshid OM, et al: Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 121(1):78, 2013
Fleming GF, Filiaci VL, Marzullo B, et al: Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 132(3):585, 2014
Frenel JS, Le Tourneau C, O’Neil B, et al: Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the Phase Ib KEYNOTE-028 Trial. J Clin Oncol 35(36):4035, 2017
Friedlander M, Gebski V, Gibbs E, et al: Health-related quality of life and patient-centered outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol 19(8):1126, 2018
Gockley AA, Rauh-Hain JA, Del Carmen MG: Uterine leiomyosarcoma: a review article. Int J Gynecol Cancer 24(9):1538, 2014
Gordon AN, Tonda M, Sun S, et al: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95(1):1, 2004
Herzog TJ, Monk BJ, Rose PG, et al: A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. Gynecol Oncol 132(3):517, 2014
Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482, 2008 Hesketh PJ, Kris MG, Basch E, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240, 2017
Ison G, Howie LJ, Amiri-Kordestani L, et al: FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res 24(17):4066, 2018
Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331, 2009
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244, 2015
Khuri FR: Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356(24):2445, 2007
Liu JF, Barry WT, Birrer M, et al: Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 15(11):1207, 2014
Long HJ III, Bundy BN, Grendys EC Jr., et al: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21):4626, 2005
Makker V, Rasco DW, Vogelzang NJ, et al: Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: updated results. J Clin Oncol 36(15 suppl):5596, 2018
Mancari R, Signorelli M, Gadducci A, et al: Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecol Oncol 133(3):531, 2014
Markman M, Blessing J, Rubin SC, et al: Phase II trial of weekly paclitaxel (80 mg/m2 ) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101(3):436, 2006
Mileshkin L, Antill Y, Rischin D: Management of complications of chemotherapy. In Gershenson DM, McGuire WP, Gore M, et al (eds): Gynecologic Cancer Controversies in Management. Philadelphia, Elsevier, 2004, p 618
Mirza MR, Monk BJ, Herrstedt J, et al: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154, 2016
Oza AM, Matulonis UA, Malander S, et al: Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/ NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol 19(8):1117, 2018
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252, 2012
Park JY, Jin KL, Kim DY, et al: Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol 125(1):80, 2012
Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302, 2014
Pujade-Lauraine E, Ledermann JA, Selle F, et al: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18(9):1274, 2017
Rizzo JD, Brouwers M, Hurley P, et al: American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996, 2010
Roila F, Hesketh PJ, Herrstedt J, et al: Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20, 2006
Slomovitz BM, Lu KH, Johnston T, et al: A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23):5415, 2010
Swisher EM, Lin KK, Oza AM, et al: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18(1):75, 2017
Tew WP, Colombo N, Ray-Coquard I, et al: Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120(3):335, 2014
Tewari KS, Sill MW, Long HJ 3rd, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734, 2014
Tinker AV, Gebski V, Fitzharris B, et al: Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously receivid paclitaxel—ANZGOG 02-01. Gynecol Oncol 104(3):647, 2007
Tonia T, Mettler A, Robert N, et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12:CD003407, 2012
Weinberg LE, Lurain JR, Singh DK, et al: Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol 121(2):285, 2011
Труды отечественных авторов при подготовке статей по гинекологии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.
